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Abstract
Biological studies of matrix metalloproteinase sensitive drug delivery systems
Cancer, which is a group of diseases characterized by cells with elevated replication rate
and compromised DNA damage response, is often treated with cytotoxic drugs, chemother-
apeutics, inducing DNA damage that results in cell death. The use of chemotherapeutics in
the clinic, however, is limited due to severe side effects as a result of drug distribution to
healthy tissues. To enhance efficacy of treatment and improve life quality of patients, tumor
specific drug delivery strategies, such as liposome encapsulated drugs, which accumulate in
tumor tissue, has gained increased attention. Several strategies have been developed to tar-
get tumor tissue, however, liposomal systems developed so far rely on passive drug diffusion
or unspecific association between liposomes and cells after accumulation in tumor tissue,
resulting in low drug efficiency. Therefore, development of rationally designed systems for
delivery of drugs to specific tissues or cells utilizing biological knowledge of cancer tissue is
getting increased attention.
In this thesis a novel matrix metalloproteinase-2 (MMP-2) sensitive poly-ethylene glycol
(PEG) coated liposomal drug delivery system for treatment of cancer was developed. The
system exploits the increased MMP-2 activity present in tumor tissue as a site-specific trigger
of liposomal activation and controlled drug release after accumulation due to the enhanced
permeability and retention effect. Enzymatic activity of MMP-2 results in shedding of a novel
PEG coating, consisting of a negatively charged lipopeptide-PEG conjugates containing a
MMP-2 cleavable peptide, which leads to cationic liposomes with enhanced ability to interact
with negatively charged cell membranes.
Activation of the liposomal formulation developed here resulted in enhanced association of
liposomes with cancer cells in vitro and in addition, the liposomes were not associated with
phagocytosing cells in human blood without prior enzymatic activation. Encapsulation of
oxaliplatin resulted in significantly increased toxicity compared with both the free drug and
oxaliplatin encapsulated in PEG-coated neutral liposomes in vitro. High MMP-2 expression
and activity was furthermore observed in human clinical samples of different types of cancer
as well as in patient-derived colon cancer xenografts in mice, whereas only low concentrations
of pro-enzymes were observed in healthy mouse tissues. These data support the use of MMP-
2 as a trigger for liposomal activation in tumor tissue. Thus, this new strategy provides a
promising system for specific delivery of encapsulated drugs and controlled release in tumor
tissues, resulting in enhanced drug bioavailability and decreased systemic side effects.
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In addition, we investigated the interaction between liposomes and cell populations in
the blood, resulting in a novel liposomal system for specific targeting to CD14+ monocytes.
Monocytes play an important role in inflammatory diseases, which are commonly treated with
steroids, through their secretion of proinflammatory cytokines, such as TNF-α and IL-1β.
However, the use of these drugs has limitations due to side effects as a result of distribution
to healthy tissues, which can be circumvented by the use of specific drug delivery systems
targeting the inflammatory cells.
We found that liposome formulations with a positive charge between 7.5 - 10 % were
optimal for targeting specific to monocytes and it was observed that this association rapidly
occurred in freshly drawn human blood. It was furthermore revealed that the use of newly
drawn blood was essential for mimicking in vivo conditions closest possible, as the monocytes
ability to phagocyte liposomes relatively fast declined after the blood was drawn. In addition,
we demonstrated that these formulations were not toxic to cells in vitro. The formulations
described in this study enable specific targeting to monocytes potentially resulting in enhanced
inflammatory effect and decreased side effects of anti-inflammatory drugs.
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Dansk resume
Biologiske studier af matrix metalloproteinase følsomme systemer til levering af lægemidler
Cancer, der er en gruppe af sygdomme karakteriseret ved øget celle deling og nedsat funktion
af DNA reparationsmekanismer, behandles ofte med cytotoksiske lægemidler, kemoterapeu-
tika, der sl˚ar celler ihjel ved at p˚aføre dem DNA-skade. Den kliniske brug af kemoterapi er
begrænset af alvorlige bivirkninger, der skyldes fordeling af lægemidler til raskt væv. Tumor
specifikke systemer til levering af lægemidler, s˚asom liposomer, har f˚aet øget opmærksomhed
i forsøg p˚a at forbedre behandlingseffekten samt patienternes livskvalitet. De systemer, der
er blevet udviklet indtil nu, har efter ophobning af liposomer i tumorvæv været afhængige
af passiv diffusion eller uspecifik associering af liposomer med celler, hvilket har resulteret i
lav effektivitet af de indkapslede lægemidler. Derfor har logisk designede systemer, der kan
levere lægemidler til specifikke væv eller celler baseret p˚a biologisk forst˚aelse af specifikke
sygdomme, f˚aet øget opmærksomhed.
I denne afhandling beskrives et nyt MMP-2 følsomt pegyleret liposomalt system til brug i
cancerbehandling. Systemet udnytter den øgede MMP-2 aktivitet i tumorvæv til aktivering
af liposomer, efter de er ophobet i tumorvæv, samt kontrolleret frigivelse af lægemidler.
Enzymaktivitet resulterer i fjernelsen af et negativt ladet PEG-lag, best˚aende af et negativt
ladet lipopeptid-PEG konjugat indeholdende et peptid, der kan spaltes af MMP-2. Dette
medfører positivt ladede liposomer med øget tendens til at interagere med negativt ladede
cellemembraner.
Aktivering af den nye liposomale formulering resulterede i øget associering af liposomer
med cancerceller in vitro. Derudover blev det vist, at liposomerne ikke associerede med
fagocyterende celler i humant blod, med mindre de først var blevet aktiveret enzymatisk.
Indkapsling af oxaliplatin resulterede i signifikant forøget toksicitet sammenlignet med det
frie stof samt oxaliplatin indkapslet i pegylerede neutrale liposomer in vitro. Høj MMP-2
aktivitet blev observeret i flere forskellige typer kliniske cancer prøver samt i musemodeller,
der havde f˚aet transplanteret koloncancer fra patienter, hvorimod kun lave koncentrationer
af pro-enzymer blev observeret i raskt musevæv. Disse data støtter brugen af MMP-2 som
en aktiv aktiveringsmekaniske til specifik levering af lægemidler til tumorvæv. Denne strategi
skaber derfor grundlag for et lovende system til specifik levering af indkapslede lægemidler
og kontrolleret frigivelse i tumorvæv, hvilket resulterer i øget lægemiddel tilgængelighed.
Vi undersøgte desuden interaktionen mellem liposomer og cellepopulationer i blodet, hvilket
resulterede i udviklingen af et nyt system, der specifikt rammer CD14+ monocytter. Mono-
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cytter spiller er vigtig rolle i flere inflammatoriske sygdomme, der ofte behandles med steroi-
der, da de udskiller proinflammatoriske cytokiner s˚asom TNF-α og IL-1β. Den kliniske brug
af disse stoffer er begrænset grundet bivirkninger, der er et resultat af levering af lægemid-
ler til raskt væv. Dette kan omg˚as ved brug af liposomale systemer, der specifikt rammer
inflammatoriske celler.
Vi kunne konkludere, at en positiv ladning mellem 7.5 - 10 % var optimal til at f˚a lipo-
somerne til specifikt at associere med monocytter, samt at denne associering skete hurtigt i
frisktappet humant blod. Det blev derudover vist, at frisktappet blod var nødvendigt for at
efterligne in vivo forhold s˚a meget som muligt, da monocytternes evne til at fagocytere hur-
tigt blev forringet efter blodet var tappet. Disse formuleringer viste sig ikke at være toksiske
for celler in vitro. Formuleringen, der beskrives her, gør det muligt at opn˚a specifik lever-
ing af lægemidler til monocytter og dermed opn˚a en øget inflammatorisk effekt og samtidig
mindske bivirkninger.
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1 Introduction
1.1 Cancer
In the human body, cell multiplication and cell death is tightly regulated to satisfy the specific
needs of tissues and organs. Normal cells follow a carefully controlled path of growth, division,
and differentiation as a result of multiple cell cycle checkpoints that ensure genome integrity.
Progression through critical events of the cell cycle, such as DNA replication, chromosome
segregation, and repair of damaged DNA, are strictly regulated. If damage cannot be repaired,
programmed cell death (apoptosis) is induced in the cell to avoid accumulation of mutations,
which are permanent, structural alterations in the DNA, otherwise passed on to daughter cells
(Dai & Grant, 2010; Lukas et al., 2011). Mutations in genes regulating essential pathways
of cell function enable cancer cells to avoid the normal cell cycle regulation and continue
to grow and divide in the presence of DNA damage, resulting in a mass of abnormal cells
proliferating out of control (Hanahan & Weinberg, 2011).
Proliferation of cells is tightly regulated by growth and anti-growth signals, in form of cy-
tokines and hormones, to maintain tissue homeostasis. Cancer cells, however, have acquired
the ability to generate their own growth signals, reducing their dependency on stimulation
from the surrounding microenvironment, and are in addition insensitive to anti-growth fac-
tors inhibiting proliferation of normal cells (Hynes, 2000; Witsch et al., 2010). In addition,
the cell itself contains an intrinsic program that limits cell proliferation, as a normal cell
only have capacity of 60 - 70 doublings due to loss of telomeres. Cancer cells, however,
have acquired the ability of telomere maintenance, mainly by up-regulation of the telomerase
enzyme, resulting in unlimited replication potential. Furthermore, cancer cells are resistant
to apoptosis, which commonly occur through mutations in the p53 tumor suppressor gene
leading to inactivation of p53 protein, a key component of the DNA damage sensor system
(Chin et al., 1999; Shay & Wright, 2000; Hanahan & Weinberg, 2000).
In theory, these cellular changes enable the cancer cells to proliferate unlimited, however,
supply of oxygen and nutrients is essential for cell survival, hence cells have to be within
reach of a capillary blood vessel. Normal cells cannot induce angiogenesis, therefore, to be
able to increase in size the tumor cells have to acquire the ability to encourage blood vessel
growth (Bergers & Benjamin, 2003). Furthermore, the tumor will eventually be limited by
the surrounding cells and connective tissues if they cannot migrate through them. Most
types of cancers metastasize, resulting in secondary tumors in other part of the body, which
is the cause of death of most cancer patients (Sporn, 1996). Two events enable cancer
cells to metastasize: changes in the physical coupling of cells to their microenvironment, due
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to changes in expression of cell-cell adhesion molecules and integrins, and increased expres-
sion of matrix-degrading proteases, such as matrix metalloproteinases (MMPs) (Hanahan &
Weinberg, 2011).
1.1.1 The tumor microenvironment
In response to tissue damage, a wide array of chemical signals initiate and maintain an appro-
priate host response, which is designed to heal the injured tissue. Chemokines, which are a
family of chemotactic cytokines, are involved in activation and direct migration of neutrophils
and monocytes from the circulation to the aﬄicted site (Luster, 1998). Neutrophils, involved
in phagocytosis of damaged tissue and secretion of cytokines to recruit monocytes, are the
first cells to arrive at the site of injury. Subsequently, monocytes migrate to the damaged
site and differentiate to macrophages, which are the main producers of pro-inflammatory cy-
tokines and reactive oxygen species (ROS). They phagocytose neutrophils as part of resolving
the inflammation. Fibroblast activation at the site of injury results in induction and activation
of proteolytic enzymes, such as MMPs, necessary for remodeling of the extracellular matrix
and for angiogenesis. When wound healing is completed, the enhanced proliferation and
inflammation subsides, inflammation resolves, and normal tissue homeostasis returns (Kalluri
& Zeisberg, 2006; Eming et al., 2007; Liddiard et al., 2011).
The tumor microenvironment, which plays a major role in development and progression
of cancer, resembles the inflammatory response in a healing wound, promoting cell prolifera-
tion, angiogenesis, turnover of extracellular matrix (ECM), and cell motility (Dvorak, 1986).
Cancer cells have acquired the ability to produce cytokines and chemokines involved in re-
cruitment of neutrophils, monocytes, fibroblasts, and endothelial cells as well as vascular
endothelial growth factor (VEGF). As observed in healing wounds, activated fibroblasts and
infiltrating inflammatory cells in the cancerous tissues secrete cytokines and proteolytic en-
zymes. However, the cytokines function as growth factors for cancer cells and instead of
being involved in tissue reconstitution, the enzymes are involved in creating space for cancer
cell proliferation, resulting in enlargement of the tumor, and metastasis (Coussens & Werb,
2002; Eming et al., 2007).
Cancerous tissues, which are less organized when compared to normal tissue, are complex
structures of malignant cells surrounded by a stroma of non-malignant cells, all of which
are embedded in newly formed blood vessels that architecturally differ from their normal
counterparts (Fig. 1.1). In the adult body the vasculature is usually quiescent and only
the female reproductive organs and injured tissue require angiogenesis, which rapidly leads
to mature and stable blood vessels. Tumors, on the other hand, have lost the appropriate
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balances between pro- and anti-angiogenic signals, resulting in that tumor blood vessels are
irregularly shaped, dilated, and can have dead ends. They are not organized into venules,
arterioles, and capillaries as vessels are in normal tissues (Bergers & Benjamin, 2003).
In addition, integration of pericytes, which cover normal blood vessels and are required for
vessel stabilization, into the capillaries are abnormal in tumor tissues, resulting in immature
and leaky vessels contributing to metastasis due to enhanced permeability of cancer cells
from the tumor (Raza et al., 2010). The lack of a mature pericyte cover results in that
the pore size of tumor microvessels, which varies from 100 to 780 nm in diameter, is much
larger than the junctions in normal tissue, which usually are less than 6 nm except from
organs with fenestrated endothelium, such as the spleen and liver with pore sizes of 150
nm (Drummond et al., 1999). Thus, cancerous tissues differ from normal tissues in several
aspects; (i) the newly formed blood vessels are irregular and leaky due to lack of a pericyte
cover and overproduction of VEGF, (ii) there is no lymphatic drainage, and (iii) the tissues
express high levels of enzymes, not present in healthy tissues, due to activation of fibroblasts
in the tumor stroma.
Figure 1.1: Tumor microenvironment: the wound that does not heal. (A) Normal tissues have a
highly organized architecture, and wound healing follow a tightly controlled program.
(B) Tumor tissues are complex structures of malignant cells surrounded by a stroma of
non-malignant cells, such as fibroblasts and immune cells, embedded in newly formed,
irregular blood vessels (Coussens & Werb, 2002).
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1.2 Treatment of cancer
Due to the huge variation in cancers, of which there exits more than 100 different types
depending on the tissue of origin (Hanahan & Weinberg, 2000), there is an equally huge
variation in cancer treatment. Generally, it is possible to cure a patient with a solid tumor by
surgically removing the tumor tissue if it has not yet metastasized, however adjuvant therapy,
including radiation therapy, chemotherapy, and biologics, is often administered after surgical
resection in an attempt to reduce recurrent disease. The therapeutic index, which is the
ratio between the dosage of a drug causing therapeutic effects and the dosage causing a side
effects, is used to indicate the safety of drugs.
Radiation therapy, which is the use of ionizing radiation in cancer treatment, is used to
treat tumors of known locations that cannot be removed by surgery or after surgery to
decrease the risk of recurrent disease (Darzynkiewicz et al., 2009). Radiation therapy, which
may be curative in some types of cancers localized to one area, can either damage DNA
directly or create charged particles (free radicals) within the cells that can in turn damage
the DNA (Missailidis & Perkins, 2007).
After a cancer has spread it is nearly impossible to remove all diseased tissue by surgery
and patients are usually submitted to chemotherapy, sometimes in combination with biologics
(Hubbard & Alberts, 2010; Darzynkiewicz et al., 2009). Where chemotherapy affects and
destroys cancer cells directly (cytotoxic), biologics stimulate the body’s immune system.
In the treatment of cancer, these drugs are used to recognize and destroy cancer cells.
Biologics used for cancer treatment include monoclonal antibodies, which target antigens
involved in cancer progression, and cytokines, such as interferon (IFN)-α2 and interleukin
(IL)-2. The monoclonal antibody Bevacuzimab (Avastin, Roche, Basel, Switzerland) function
by inhibiting angiogenesis by binding to VEGF resulting in decreased tumor cell proliferation
due to lack of oxygen and nutrients (Ferrara et al., 2005). Based on results of phase III clinical
trials that demonstrated benefits of the combination of chemotherapy and bevacizumab, it is
now considered standard therapy in the first-line treatment for metastatic colorectal cancer
(Hurwitz et al., 2004; Hubbard & Alberts, 2010; Karaca-Mandic et al., 2011). IFN-α2
have been reported to have efficacy in myeloproliferative neoplasms, such as polycythemia
vera and essential thrombocythemia (Kiladjian et al., 2008). IL-2 is an essential factor
for proliferation of T-leukocytes and enhances various T-leukocyte and natural killer (NK)
cell functions (Shaker & Younes, 2009). IL-2 is approved for treatment of metastatic renal
cancer and metastatic melanoma, based on the ability to mediate durable complete responses
(Turcotte & Rosenberg, 2011).
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1.2.1 Chemotherapy
Most cancer cells have an elevated mitotic index and compromised DNA damage response
(DDR) making them sensitive to DNA damage, thus some of the most effective chemother-
apeutic drugs currently used in the clinic act by DNA damage induced apoptosis (Hurley,
2002; Darzynkiewicz et al., 2009) (Table 1.1). Since chemotherapy is damaging to cells with
a high division rate, it also affects cells that divide fast under normal circumstances. Hence,
the toxicity of chemotherapy is a result of side effects induced in normal tissues with relatively
high replication rates, such as the digestive tract, bone marrow, and hair follicles, limiting
the use of chemotherapeutics in the clinic (Beeharry & Broccoli, 2005; Kuijpers et al., 2010).
Therefore, to reduce side effects, several different drugs are usually given simultaneously in
combination chemotherapy. The rationale for this is that drugs, which function through
different cytotoxic mechanisms and do not have the same dose-limiting side effects, can be
administered together at full doses, resulting in enhanced therapeutic efficacy (Mayer, 2009).
Group Subgroup Drug examples
Platinum drugs Cisplatin
Carboplatin
Oxaliplatin
Antimicrotubule agents Vinca alkaloids Vinblastine
Vinorelbine
Taxanes Paclitaxel
Docetaxel
Antimetabolites Methotrexate
Fluoropyrimidines 5-fluorouracil (5FU)
capecitabine
Cytocine Arabinose Cytarabine
Gemcitabine
Antitumor Antibiotics Actinomycin D
Mitomycin C
Bleomycin
Anthracyclines Doxorubicin
Daunorubicin
Podofylotoxines Etoposide
Teniposide
Camptothecines Irinotecan
Topotecan
Alkylating Agents Cyclophosphamide
Nitrogen mustard-based agents Mechorethamine
L-phenylalanine mustard-based agents Mephalan
Nitrosoureas Carmustine
Alkane sulfonates Busulfan
Table 1.1: Overview of drugs used in cytotoxic chemotherapy (Missailidis, 2008).
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In treatment of e.g. colorectal cancer, leucovorin (LV) have been demonstrated to enhance
the anti-neoplastic effects of 5-fluorouracil (5FU). LV, also known as folinic acid (a more sta-
ble, synthetic derivative of folic acid), is not a chemotherapy drug, but is often administrated
in combination with chemotherapy, either to make the treatment more effective or to reduce
side effects. Both LV (FOL: folinic acid) and 5FU (F: fluorouracil) can be combined with
irinotecan (IRI) or oxaliplatin (OX) with the treatment acronyms FOLFIRI or FOLFOX, re-
spectively. All four drugs are used together in the treatment regime FOLFIRINOX (Goodwin
& Asmis, 2009; Hubbard & Alberts, 2010; Conroy et al., 2011a), which also is used as first
line treatment of metastatic pancreatic cancer (Conroy et al., 2011b).
1.3 Matrix metalloproteinases
The lethal outcome of most cancers is due to metastasis of the primary tumor, as the spread-
ing of cancer cells often results in secondary tumors in vital organs such lungs, liver, and
bone (Sporn, 1996). Metastasis involves invasion of tumor cells into peripheral tissue, which
requires crossing of physical barriers, such as basement membranes. Several enzymes, includ-
ing the MMPs, ADAM (a disintegrin and metalloproteinase), and ADAMTS (a disintegrin
and metalloproteinase with thrombospondin motifs), have been reported to be involved in
tumor growth and metastasis by degradation of basal membranes as well as components of
the ECM (Kessenbrock et al., 2010). The different types of non-maligant stromal cells within
the tumor tissue produce a specific set of proteinases and proteinase inhibitors, which are
released into the extracellular space (Fig. 1.2A).
MMPs are a family of structurally related zinc-dependent endopeptidases first described
almost half a century ago, when Gross & Lapiere (1962) made the exciting discovery of
a collagen degrading activity in tadpoles during metamorphosis. This activity was found
to be caused by an interstitial collagenase, now known as collagenase-1 or MMP-1. The
human MMP family currently encompasses 23 members that based on their structure and
substrate preferences can be divided into eight groups, three of which are membrane-type
MMPs (MT-MMPs) and five of which are secreted (Table 1.2 and Fig. 1.2B) (Egeblad &
Werb, 2002). Even though the MMPs have different substrate specificity and affinity, there
is overlap between the substrates of the different groups of MMPs. In addition, some MMPs
are involved in proteolytic activation of other family members (Yong et al., 2001).
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Figure 1.2: The MMP family and its expression by stromal cells. (A) Expression of proteinases
and their inhibitors in stromal cells. Adapted from Kessenbrock et al. (2010). (B) The
MMP family grouped on basis of their structure (Egeblad & Werb, 2002)
1.3.1 Regulation of matrix metalloproteinases
MMPs are potent proteolytic enzymes with high ECM-degrading activity, hence potentially
disastrous effect on the microenvironment. Therefore, the expression and activity of MMPs is
tightly regulated, at both transcriptional and post-transcriptional levels. MMPs are expressed
in low concentrations and their cellular localization and activity is tightly controlled through
three important mechanisms. The first regulation is at transcription level, as most MMPs
are not constitutively expressed in the tissues, but are transcribed after cell activation pro-
moted by inflammatory cytokines, growth factors, or cell-cell or cell-matrix interactions. The
second mechanism of MMP regulation is post-translational modifications. Most MMPs are
synthesized and secreted as inactive proenzymes that have to be activated proteolytically by
extracellular proteases. Their latency is maintained as a result of the interaction of a cysteine
residue near the C-terminal end of the pro-domain with the zinc ion of the catalytic site. This
interaction can be disrupted by enzymatic removal of the pro-domain, either by activation
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Structural class MMP designation Common name(s) MMP substrates
Minimal-domain MMP-7 Matrilysin MMP-1, -2, & -9
PUMP1
MMP-26 Matrilysin-2
Simple hemopexin MMP-1 Collagenase-1 MMP-2 & -9
domain Interstitial collagenase
MMP-3 Stromelysin-1 MMP-1, -7, -8, -9, & -13
MMP-8 Collagenase-2
MMP-10 Stromelysin-2 MMP-1 & -8
MMP-12 Metalloelastase
MMP-13 Collagenase-3 MMP-9
MMP-19 MMP-18
MMP-20 Enamelysin
MMP-27
Gelatin-binding MMP-2 Gelatinase A MMP-1, -9, & -13
72-kDa type IV collagenase
MMP-9 Gelatinase B
92-kDa type IV collagenase
Furin-activated MMP-11 Stromelysin-3
and secreted MMP-28 Epilysin
Vitronectin-like insert MMP-21
Transmembrane MMP-14 MT1-MMP MMP-2 & -13
MMP-15 MT2-MMP MMP-2
MMP-16 MT3-MMP MMP-2
MMP-24 MT5-MMP MMP-2
GPI-linked MMP-17 MT4-MMP
MMP-25 MT6-MMP
Type II transmembrane MMP-23* MMP-21/MMP-22
Table 1.2: Overview of the MMP family. *Gururajan et al. (1998) identified two new MMP genes,
called MMP21 and MMP22. These are now designated MMP23A and MMP23B, since
the nucleotide sequences was almost identical (Egeblad & Werb, 2002). There overlap
in substrate specificity between the different groups (Yong et al., 2001).
of the plasminogen-plasmin cascade or by other MMPs (Table 1.2), a mechanism known as
the cysteine switch (Wart & Birkedal-Hansen, 1990; Page-McCaw et al., 2007) (Fig. 1.3).
Non-proteolytic compounds such as sulphydryl-reactive agents (4-aminophenylmercuric ac-
etate (APMA)) and denaturants (urea and sodium dodecyl sulfate (SDS)) can also activate
zymogens. In addition, a subset of MMPs, including the MT-MMPs, contains a cleavage site
for furin-like prohormone convertases between the propeptide and catalytic domains. These
enzymes are activated during secretion and expressed in the active form on the surface.
A third way to control MMP activity is by the interaction of activated MMPs with endoge-
nous inhibitors. The most intensively studied endogenous MMP inhibitors are the four tissue
inhibitors of metalloproteinases (TIMPs), TIMP-1, -2, -3 and -4, which reversibly can inhibit
MMPs in a 1:1 stoichiometric fashion by binding to the catalytic site. The tissue-specific
expression and ability to inhibit various MMPs differ between these inhibitors (Woessner,
8
1.3 Matrix metalloproteinases
1991; Morgunova et al., 2002). In addition, α2-macroglobulin, an abundant plasma protein,
is the main inhibitor of MMPs present in tissue fluids. MMPs bound to α2-Macroglobulin
are irreversibly cleared by endocytosis (Egeblad & Werb, 2002).
Figure 1.3: Activation of MMPs can be accomplished by enzymatic removal of the pro-domain or
chemical modification of the cysteine residue, which both liberates the zinc ion in the
active site (Page-McCaw et al., 2007).
1.3.2 Function of matrix metalloproteinases
MMPs are involved in tumor progression and metastasis, however, their function is complex
and still not fully understood. These enzymes are not evolved to harm the human body,
but are responsible for normal physiological tissue turnover and the latent forms of most
MMPs are usually present at low concentrations under normal conditions. In normal physio-
logical processes, such as tissue and bone remodeling, embryonic development, angiogenesis,
and wound healing, they play a key role in the breakdown of ECM components and base-
ment membranes (Page-McCaw et al., 2007). Furthermore, MMP proteolysis has important
functions besides degradation of structural components, since they affect various signaling
pathways that modulate the biology of tissues and individual cells. MMPs can create space
for cell migration (Nagase, 1998; Koshikawa et al., 2000), produce biologically active cleav-
age fragments (Scho¨nbeck et al., 1998; Gearing et al., 1994; Bergers et al., 2000) as well as
activate, deactivate, or modify signaling molecules activity in the tissues (McQuibban et al.,
2000; Raza & Cornelius, 2000; Sternlicht & Werb, 2001; Mott & Werb, 2004).
Due to their high proteolytic capacity, dysregulated expression of MMPs and their inhibitors
contribute to a number of pathologic conditions. MMP activity can be detected in diseased or
inflamed tissues, including Crohn’s disease (Kirkegaard et al., 2004), coronary artery disease
(Chu et al., 2011), and cancer (Wagner et al., 1996). In cancer development and progression
they are involved in tissue invasion of the tumor and cancer cell intravasation into blood
vessels requires ECM remodeling and down regulation of cellular adhesion (Fig. 1.4 (1)).
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Tumors are highly vascularized tissues and angiogenesis can be induced by release of VEGF,
which is mainly facilitated by MMP-9 (Fig. 1.4 (2)). In addition, MMPs, which are potent
regulators of inflammation, are involved in recruitment of inflammatory cells to the site of
the tumor, for example by converting TNF-α (Fig. 1.4 (3)). Metastasis results in the
dissemination of malignant cells to sites distant to the primary tumor that may be primed for
metastasis by inflammatory cells and hematopoietic progenitor cells (HPCs). MMP-9 and
MMP-2 may be involved development of these premetastatic niches by releasing factors such
as VEGF and Kit ligand, which recruits HPCs from the bone marrow (BM) (Fig. 1.4 (4)).
Figure 1.4: Functions of MMPs in the tumor microenvironment. The different stages of tumor
progression and metastasis can be modulated by MMPs and other extracellular pro-
teinases. MMPs are mainly secreted by non-malignant stromal cells, such as neu-
trophils, macrophages, and endothelial cells, infiltrating the tumor tissue (Kessenbrock
et al., 2010).
10
1.3 Matrix metalloproteinases
1.3.3 The gelatinases
The MMP subgroup known as the gelatinases, or the type IV collagenases, comprises two
members; gelatinase A (MMP-2, 72-kDa type IV collagenases) and gelatinase B (MMP-9,
92-kDa type IV collagenases) (Hibbs et al., 1985, 1987). These enzymes differ from the other
MMPs in their substrate affinity resulting from their unique structure. They contain three
repeats of a type II fibronectin sequence in the catalytic domain, which facilitates high affinity
for gelatin, which is the breakdown product of collagen; a structural protein in connective
tissue, skin, and bones (Eastoe, 1955). They also have high affinity for collagen type IV,
which constitutes a major part of basement membranes (Liotta et al., 1980; Woessner, 1991;
Hudson et al., 1993).
The latent form of MMP-2, pro-MMP-2 (Fig. 1.5A), is constitutively expressed by most
stromal cells, including fibroblasts, endothelial cells, mast cells, macrophages, and dendritic
cells (DCs) (Fig. 1.2A), hence regulation occurs by strictly controlled activation and inhibi-
tion (Kessenbrock et al., 2010). The activity of MMP-2 is controlled in a unique manner by
activation on the cell surface of macrophages, fibroblasts, and endothelial cells by the trans-
membrane MMP-14, also known as MT1-MMP (Strongin et al., 1995; Morgunova et al.,
1999; Worley et al., 2003). TIMP-2, which is a potent inhibitor of MMP-2, is involved
in this special pro-MMP-2 activation mechanism where MT1-MMP first binds to TIMP-
2, which then binds to pro-MMP2, positioning the proenzyme for activation by a second
molecule of MT1-MMP (Itoh et al., 1998; Wang et al., 2000) (Fig. 1.5B). This activation
mechanism localizes the proteolytic activity of MMP-2 to the cell surface. The activity of
MMP-2 is furthermore regulated by inhibition with TIMP-2, which is secreted by cells ex-
pressing pro-MMP-2 except from mast cells. The ratio between secretion of pro-MMP-2 and
TIMP-2 determines the activity, however, this regulation is very complex due to the need for
TIMP-2 in the activation of MMP-2. Wang et al. (2000) demonstrated that the dominant
physiological function of TIMP-2 in vivo is activation of MMP-2.
Basal levels of MMP-9 are usually low, but secretion can be induced by different cytokines,
such as TNF-α. MMP-9 is mainly secreted by inflammatory cells, such as neutrophils,
lymphocytes, monocytes, and dendritic cells, but it is also expressed by stromal cells such as
fibroblasts, mast cells, and macrophages (Fig. 1.2A) (Opdenakker et al., 2001; Corry et al.,
2004; Kessenbrock et al., 2010). Pro-MMP-9 is activated by plasmin and other MMPs,
such as MMP-1, -2, -3, -7, and -13 (Fridman et al., 1995; Ramos-DeSimone et al., 1999;
Yong et al., 2001) and is inhibited by TIMP-1 expressed by all MMP-9-expressing cells in the
tissues as well as endothelial cells (Okada et al., 1992; Kessenbrock et al., 2010).
To be able to metastasize, cancer cells must detach from both neighboring cells and the
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Figure 1.5: Structure and activation of pro-MMP-2. (A) Prodomain (red), catalytic domain (blue),
fibronectin domains (green), and hemopexin domain (yellow) of pro-MMP-2. Calcium
and zinc ions are indicated in magenta and red, respectively. Asterisk indicates cleavage
site for MT1-MMP (Morgunova et al., 1999). (B) Activation of MMP-2 by MT1-
MMP. MT1-MMP (blue) is activated during secretion by furin. TIMP-2 (red) binds
to the active catalytic domain of MT1-MMP, and the complex recruits pro-MMP-2
(green) by interactions of TIMP-2 with the hemopexin domain of pro-MMP-2. MT1-
MMP thereby brings pro-MMP-2 close to the another MT1-MMP, which removes the
pro-domain of MMP-2 (Brinckerhoff & Matrisian, 2002).
surrounding matrix. CD44, the main receptor for hylauronan, bind to the ECM, and cleavage
of this molecule by MT1-MMP is needed for cell migration. CD44 also binds MMP-9, thereby
localizing the enzymatic activity to the cell surface, which is required for MMP-9 to promote
tumor invasion and angiogenesis. However, cleavage of CD44 by MMP-14 probably also
results in decreased MMP-9 activity at the cell surface (Egeblad & Werb, 2002).
In addition, MMP-9 have been reported to play an important role in angiogenesis where it
contributes to neovascularization by regulating the bioavailability of VEGF, which is one of
the most important pro-angiogenic factors (Bergers et al., 2000). VEGF ligands are tightly
bound to the ECM in latent forms and are released and activated by enzymatic activity
(Grunstein et al., 1999).
1.3.4 MMP inhibitors in cancer treatment
MMPs have long been considered essential for invasion and metastasis of cancer cells (Liotta
et al., 1980; Sato et al., 1994) and the use of several MMP inhibitors (MMPIs) in cancer
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treatment have therefore been investigated. Due to poor bioavailability, the first-generation
MMPIs were rapidly replaced by a second-generation orally active drugs (Whittaker et al.,
1999). Phase I clinical trials, which were designed to evaluate drug safety, revealed that
long-term MMPI-treatment lead to musculoskeletal pain and inflammation, complications
not described in preclinical studies. These side effects resulted in that lower dosages of
MMPIs were used in subsequent trials, although the conditions were reversible. In an at-
tempt to decrease side effects, the ”deep-pocket” MMPIs prinomastat (Pfizer ApS, DK) and
tanomastat (Bayer A/S, DK) were developed. These were potent inhibitors of MMP-2 and
-9 but less effective against MMP-1, -7, and -11. Prinomastat, however, still caused similar
side effects as seen with previously developed MMPIs (Whittaker et al., 1999).
Phase II trials, which were designed to investigate drug efficacy, turned out to be challeng-
ing, since conventional measures of efficacy such as reduction in tumor size could not be used
for evaluation of drug efficacy, since these drugs were cytostatic (cells are growth-arrested)
rather than cytotoxic (cells are destroyed). Clinical trials have been terminated as a result
of lack of efficacy or even in one reported case because patients receiving the MMPI had
significantly poorer survival than patients receiving placebo. These studies of tanomastat
suggested that MMP inhibition can result in enhanced disease progression. Several of the
second-generation MMPIs drugs advanced to phase III clinical trials, however, the trials failed
to reach their end points of enhanced survival. Thus, due to the complex function of MMPs
in normal physiological events no treatment with MMPIs has yet been successful in enhancing
survival rate of patients (Egeblad & Werb, 2002; Coussens et al., 2002; Overall & Kleifeld,
2006).
1.4 Liposomes
Liposomes, which are small, artificial phospholipid vesicles composed of a bilayered membrane
enclosing an aqueous core (Bangham et al., 1965), were initially suggested as drug carriers
in cancer chemotherapy by Gregoriadis et al. (1974). This proposal resulted in enhanced
interest in these microscopic delivery vesicles. Several properties of liposomal formulations,
such as stability and circulation time, depend on physicochemical features related to the types
and amounts of lipids in the formulation (Barenholz et al., 2011). Lipid charge (cationic,
anionic, or neutral), length of alkyl chains, and number of unsaturated bonds, are important
for the properties of a specific liposome formulation.
Liposomes are prepared by mixing the different lipids, freezing the solution in liquid nitro-
gen, and freeze-drying to yield a lipid film, which is then re-hydrated (Fig. 1.6). Liposomes
are able to deliver a wide range of drugs, since hydrophilic drugs can be anchored in the mem-
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brane and hydrophobic drugs can be loaded into the aqueous core, either by passive loading,
where the drug is added during liposome formulation, or active loading, where the drug is
added after the liposomes are formed and loaded against a gradient (Barenholz, 2001).
Figure 1.6: Preparation of liposomes. (A) Liposomes are formed by hydration of thin lipid films
resulting in stacks of liquid crystalline bilayers become fluid and swell. The hydrated
lipid sheets self-close to form large, multilamellar vesicles (LMV). (B) Once these
particles have formed, the size is reduced by sonication or extrusion, (C) resulting in
large unilamellar vesicles (LUV) and small unilamellar vesicles (SUV). Adapted from
http://avantilipids.com.
Extensive work have been conducted to improve liposomal delivery of anti-cancer drugs,
however, liposomes have to satisfy three basic criteria to be successful in specific delivery
of drugs into tumor tissue. They have to: (i) have prolonged circulation time in the blood,
(ii) demonstrate enhanced accumulation at the site of the tumor, but not in healthy tissues,
and (iii) release the encapsulated drug in a controlled way resulting in uptake by tumor cells
(Drummond et al., 1999; Barenholz, 2001; Andresen et al., 2005).
One of the major drawbacks of early liposomal drug delivery systems was rapid recognition
and removal of liposomes by the mononuclear phagocyte system (MPS) after intravenous
(I.V.) administration, significantly decreasing the amount of drugs reaching the target site
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(Gabizon et al., 1991). The MPS consists of monocytes in the blood, their myeloid pro-
genitor cells in the bone marrow, tissue macrophages, and DCs (Fig. 1.7) (Chow et al.,
2011). Monocytes can circulate for several days, before they as a result of proinflammatory,
metabolic, or immune stimuli leave the vasculature, migrate into the tissues and differentiate
into macrophages or DCs (Gordon & Taylor, 2005; Varol et al., 2009). Tissue macrophages,
especially found in the liver, spleen, and lymphatic system, and blood monocytes have high
phagocytic activity and contribute to clearance of apoptotic host cells (Devitt et al., 1998;
Mikolajczyk et al., 2009) and foreign particles, including administrated liposomes (Huong
et al., 1998; Moghimi & Hunter, 2001; Afergan et al., 2008).
Figure 1.7: Development of cells of the MPS. The cells of the MPS arise from a common precur-
sor, the hematopoietic stem cell (HCS), which differentiates into a common myeloid
progenitor (CMP) and further into a granulocyte and macrophage progenitor (GMP).
Commitment to the mononuclear phagocyte lineage is determined at the stage of the
macrophage and DC progenitor (MDP), which give rise to monocytes and common
DC progenitors (CDPs) (Chow et al., 2011).
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1.4.1 Opsonin-dependent recognition of liposomes
The blood carries oxygen and nutrients, such as amino acids, simple sugars (e.g., glucose),
lipids (e.g., triglycerides, phospholipids, and cholesterol), and nucleotides, to the tissues
and removes waste materials and toxic gases. Blood is basically cells suspended in plasma,
consisting of water and plasma proteins, such as albumins, globulins, and fibrinogens, as
well as amino acids, carbohydrates, lipids , hormones, vitamins, and electrolytes. The main
reason for liposome recognition and elimination by cells of the MPS is adsorption of blood
proteins, opsonins, leading to opsonization and clearance from the circulation. Opsonins are
immune serum factors, such as immunoglobulins and complement protein, and non-immune
serum factors, such as fibronectin, C-reactive protein, and albumin, which bind to foreign
particles and promote phagocytosis. Complement proteins activate the complement system,
whereas binding of non-complement opsonins result in receptor-mediated uptake (Woodle &
Lasic, 1992; Ishida et al., 2002; Vonarbourg et al., 2006).
1.4.2 The complement system
The complement system, which is composed of about 30 proteins present in plasma and
expressed on the surface of immune cells, has evolved as an immediate defense against
invading pathogens. One important role of the complement system is the assembly of a
membrane attack complex (MAC) which produces a lytic pore inducing lysis of cells as well
as release of liposomal contents. Complement activation is also used to mark foreign particles
for removal by phagocytic cells through receptor-mediated recognition (Ishida et al., 2002).
Complement activation can be achieved by at least four different events: (i) fixation of
C1q proteins to an antibody or C1q receptors at the surface (the classical pathway), (ii)
binding of C3 fragments to a pathogen (the alternative pathway), (iii) binding of C-reactive
protein or serum amyloid P with C1q, resulting in activation of the classical pathway without
the presence of an antibody (pentraxin pathway), or (iv) binding of mannose-binding lectin
on mannose contained in bacteria and in viruses (lectin pathway) (Vonarbourg et al., 2006).
Activation of one of these pathways results in an enzymatic cascade, leading to formation
of a common enzyme, C3 convertase (Fig. 1.8). This protease cleaves C3, which is the most
abundant protein of the complement system, into two fragments: C3a and C3b, the latter
being the active component involved in cleavage of C5 - C9. These events result in assembly
of MACs, which are inserted into membranes and lead to formation of 10 nm diameter pore-
like structures that are able to destabilize membranes. Thus, drug release from liposomes is
facilitated by insertion of MACs in the liposomal membrane (Ishida et al., 2002).
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Figure 1.8: Illustration of the different pathways of the complement system leading to cleavage of
C3 and formation of a membrane attack complex (MAC) (Vonarbourg et al., 2006).
C3a and C3b can both be recognized by receptors on phagocytic cells leading to engulf-
ment of the bound particle. Furthermore, C3a and the cleavage products C4a and C5a,
resulting from the cleavage of C4 and C5 proteins, are strong inflammatory agents that re-
cruit inflammatory cells and modulated DC and macrophage functions (Zhou, 2012). After
activation of the alternative pathway factor B, which is released form monocytes, is cleaved
by factor D into 2 fragments: Ba and Bb. The latter, a serine protease, combines with
complement factor 3b to generate the C3 convertase (Vonarbourg et al., 2006).
Since uncontrolled complement activation can induce inflammatory and life threatening
conditions, the role of complement activation by polymers and nanoparticulate drug carriers
is receiving increasing attention. The interaction between the complement system and nano-
materials is complex, as it is affected by various factors, such as size, morphology, and surface
characteristics (Moghimi et al., 2011). It has been suggested by Chonn et al. (1991), who
analyzed both human and guinea pig serum, that liposomes containing negatively charged
phospholipids will activate the classical complement pathway, whereas incorporation of pos-
itively charged phospholipids activates the alternative pathway of complement. However,
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it was demonstrated in rat serum that both negatively and positively charged liposomes
activated the complement system via the classical pathway (Devine et al., 1994). Most re-
cently, Salvador-Morales et al. (2009) reported that lipid-polymer hybrid nanoparticles mainly
activated the alternative pathway, whereas other particle activated the classical pathway.
1.4.3 Opsonin-independent recognition of liposomes
The opsonin receptor-independent pathway involves recognition of conserved molecular pat-
terns, called pathogen-associated molecular patterns (PAMPs), such as lipopolysaccharide
(LPS), peptidoglycan (PG), lipoproteins, and lipoteichoic acids, which are products of mi-
crobial metabolism. PAMPs, which are conserved among microorganisms of a given class
and most often essential for their survival, are not expressed by eukaryotic cells and their
recognition by the innate immune system therefore signals the presence of microbial invaders,
thus an infection (Medzhitov, 2001).
In addition, cells of the MPS also recognize and phagocytose damaged or apoptotic cells
(Serhan & Savill, 2005; Ravichandran & Lorenz, 2007) (Fig. 1.9). Under physiological
condition, the negatively charged lipid phosphatidylserine (PS) is localized exclusively in the
inner leaflet of the cell membrane. Exposure of PS, which occurs in activated platelets,
sickled red blood cells, and apoptotic cells, results in recognition and removal from the blood
circulation by cells of the MPS (Schwartz et al., 1985; Fadok et al., 1992). Mikolajczyk
et al. (2009) reported that peripheral blood monocytes phagocytose apoptotic but not freshly
isolated neutrophils. They found that exposure of PS was an important for phagocytosis of
apoptotic cells, since liposomes containing PS, but not other anionic lipids, reduced binding
of apoptotic neutrophils in a dose-dependent manner.
1.4.4 Avoiding the mononuclear phagocyte system
The original challenge of implementing liposomes in the treatment of cancer was their rapid
removal by cells of the MPS, thus making substantial accumulation in tumor tissue impossible.
Reduction of the rate of liposomal uptake by the MPS was essential if liposomes should be
used as a delivery device for chemotherapeutics. The effect of particle size and charge
was recognized early by Juliano & Stamp (1975), who demonstrated that small unilamellar
liposomes were cleared less rapidly than large multilamellar vesicles. Furthermore, they found
that particle charge was an important determinant of liposomal clearance, as neutral and
positively charged unilamellar liposomes were cleared slowly compared to negatively charged
unilamellar liposomes.
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Figure 1.9: Phagocytosis of apoptotic cells. (A) At early stages of apoptosis, dying cells release
factors, such as the lipid lysophosphatidylcholine (LPC), which facilitate the recruit-
ment of phagocytes. (B) Later, the apoptotic cells start to express ’eat-me’ signals on
the surface, such as phosphatidylserine (PS), which are recognized by phagocyte-cell-
surface receptors (Ravichandran & Lorenz, 2007).
The essential step for realizing the use of liposomes as delivery vesicles in cancer treatment
turned out to be coating of liposomes with poly-ethylene glycol (PEG), a synthetic hydrophilic
polymer, which significantly decreased the uptake of liposomes by cells of the MPS resulting in
prolonged circulation-time (Allen & Chonn, 1987). These pegylated liposomes are now known
as Stealth R© liposomes (Liposome Technology Inc., Menlo Park, CA) (Allen & Hansen, 1991).
It is assumed that PEG provides steric stabilization, meaning that PEG-polymers form a
protective hydrophilic layer on the surface of liposomes. The concentration of highly hydrated
groups on the surface sterically inhibits both hydrophobic and electrostatic interactions of
blood opsonins, avoiding liposome recognition by the MPS (Blume & Cevc, 1990).
Coating of liposomes with PEG results in localization in cancerous tissue due to leaky
vasculature and lack of lymphatic drainage, an effect that often is referred to as the en-
hanced permeability and retention (EPR) effect (Matsumura & Maeda, 1986). Liposomes
are generally too large for glomerular filtration, since the kidney glomerulus have a pore size
of 40 to 60 nm, however, the sinusoidal endothelium of the liver and spleen have a pore
size of 150 nm and macrophages in these organs rapidly remove liposome from circulation.
Thus, PEG coated liposomes, which are not recognized and cleared by tissue macrophages,
selectively accumulates in tumors, with pores of 100-780 nm, through passive diffusion. They
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can pass the liver and spleen several times, but they remain at the site of the tumor due
to lack of lymphatic drainage (Drummond et al., 1999). PEG-coated liposomes have gained
increased attention as cancer specific drug delivery systems, as they significantly enhance
the amounts of drug delivered to the cancerous tissues while reducing drug concentrations
in normal tissues, resulting in decreased side effects (Allen & Martin, 2004).
1.4.5 Liposomes in cancer treatment
The most intensively investigated drug for use in liposomal delivery strategies is Doxoru-
bicin (DOX), an anthracycline which has been used since the late 1960s for treatments of
breast and esophageal carcinomas, Kaposi’s sarcoma as well as Hodgkin’s and non-Hodgkin’s
lymphomas (Minotti et al., 2004). DOX have been suggested to induce apoptosis through
oxidative DNA damage (Mizutani et al., 2005). DOX encapsulated in pegylated Stealth R©
liposomes was the first liposomal formulation to be approved by U. S. Food and Drug Admin-
istration (FDA) for clinical use in 1995 (Gabizon, 2001a). This formulation, also known as
Doxil (Janssen Biotech, Inc, Horsham, PA, USA), is approved for clinical use in the treatment
of AIDS related Kaposi’s sarcoma and recurrent ovary cancer (Goebel et al., 1996). DOX
is actively loaded into liposomes using an ammonium sulfate gradient, resulting in drug pre-
cipitation within the liposomes (Barenholz, 2001). Even though prolonged circulation time
and enhanced accumulation in tumor tissue had promising prospects for liposomal delivery
of chemotherapeutics, Doxil only demonstrated modestly increased anti-tumor efficacy com-
pared to free DOX (Matsumura et al., 2004). However, liposomal encapsulation of DOX
significantly reduced the cardiotoxicity normally associated with the free drug, by changing
drug pharmacokinetics and biodistribution (Working et al., 1999).
The stealth R© liposome is a passive drug delivery system that exploits the differences in per-
meability of blood vessels in cancerous and healthy tissues (Fig. 1.10). Release of DOX from
the liposomes is still not fully elucidated, but is suggested to involve non-specific chemical
disruption of the pH gradient retaining the drug, resulting in release of DOX without dis-
ruption of the liposomal membrane (Andresen et al., 2005). Stealth R© liposomes accumulate
in cancerous tissues due to prolonged circulation time, but large amounts are also found in
various healthy tissues such as skin, a condition known as the hand-foot syndrome (Gabizon
et al., 1994), resulting in the maximal tolerated dose of Doxil is lower than that of free DOX
(Gabizon et al., 2003). Lyass et al. (2000) demonstrated that the maximal cumulative dose
of Doxil is significantly higher than that of free doxorubicin. They observed that changes in
the dose have a significant impact on toxicity. However, because of the small group size it
was not possible to address the question of the effect of dose on therapeutic efficacy.
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Figure 1.10: Doxil accumulation in tumors. (1) Doxil circulate in the blood for up to 2 - 3 weeks
after injection. (2) Intact liposomes extravasate through gaps in tumor neovascula-
ture. (3) Drug molecules are released from liposomes. (4) Free drug molecules enter
tumor cells and induces aopotosis (Gabizon, 2001a).
In addition to Doxil, the non-pegylated formulation MyotecTM(Doxorubicin citrate, Cephalon
Limited, Oxford, UK) have been approved for treatment of metastatic breast cancer (Batist
et al., 2002) and the heat-activated liposomal formulation ThermoDox R© (Celsion Corpora-
tion, Lawrenceville, NJ, USA) is currently being investigated for treatment of hepatocellular
carcinoma and recurrent breast cancer (Yarmolenko et al., 2010). In addition, DaunoXome,
which is a liposomal formulation of daunorubicin citrate (Gilead Sciences, Foster City, CA,
USA), is approved for as first-line therapy for Kaposi’s sarcoma (Petre & Dittmer, 2007).
Another drug that have been tested for use in liposomal delivery strategies is Cisplatin,
which is a platinum based drug that is used alone or in combination with other drugs in the
treatment of several types of unresectable cancers, including bladder, ovarian, and testicular
cancer, which cannot be treated with radiation therapy. It has been used in combinations
with fluoropyrimidines and anthracyclines for treatment of advanced, gastric cancer. Cispaltin
induces apoptosis as a result of binding to DNA (Todd & Lippard, 2009).
SPI-077, a liposomal formulation of cisplatin, was developed to enhance accumulation of
cisplatin in tumor tissue and avoid side effects associated with the free drug. A phase I
studies showed decreased toxicity of SPI-077, however, enhanced accumulation of platinum
in tumor cells could not be demonstrated (Terwogt et al., 2002). A phase II study in non-
small cell cancer and head and neck cancers, was carried out but with equally disappointing
results (White et al., 2006). Recently, a phase II trial on patients with potentially platinum-
sensitive, relapsed ovarian cancer was conducted to search for enhanced in vivo efficacy of
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this formulation, however, enrollment of patients was terminated after 5 patients were treated
due to concern with the adequacy of the formulation (Seetharamu et al., 2010). Four out
of the five patients had stable disease as best response. The absence of an active trigger
of drug release provides an explanation for the lack of antitumor activity and low toxicity of
SPI-077, which in opposition to Doxil is passively loaded (Andresen et al., 2005).
Oxaliplatin, a derivate of cisplatin, is used for colorectal cancer and stage III colon can-
cer. Compared with cisplatin, oxaliplatin induces more DNA double-strand breaks in vitro,
resulting in increased cytotoxicity (Chaney et al., 2005). Potentially, this could result in
enhanced clinical activity and survival. In fact, oxaliplatin has been reported to be at least as
effective as cisplatin for advanced, unresectable gastric cancer and, furthermore, it was less
toxic and demonstrated a better tolerability profile, particularly in older patients. The toxicity
of oxaliplatin is significantly associated with increased neurotoxicity when compared to cis-
platin, however, significantly fewer thromboembolic events and less severe neutropenia was
observed, which are major cause of complications and hospitalization during chemotherapy
(Montagnani et al., 2011). Oxaliplatin, however, has low bioavailability due to partitioning
into erythrocytes (Pendyala & Creaven, 1993), hence this drug will benefit from liposomal
encapsulation, potentially increasing the therapeutic index significantly.
Until now, the only successful formulations for cancer treatment are with the anthracy-
clines, DOX and daunorubicin, assumed to be a result of active loading of these drugs. The
cispaltin formulation SPI-077, which is passively loaded, does not have a therapeutic effect,
due to lack of drug release mechanism. From these studies it is clear that for liposomes
to become a successful delivery system for various types of drugs, a way to enhance drug
bioavailability specifically in tumor tissue, while maintaining the stability of the liposomes dur-
ing circulation, has to be found. This can be achieved by (i) site-specific delivery by targeting
liposomes to cancerous tissues or - probably more importantly - by (ii) site-specific triggering
of drug release. Enhanced and specific drug release in the tumor tissue can potentially be
obtained by a combination of active targeting and active triggering.
1.5 Strategies for active targeting of liposomes to tumor tissues
To enhance specific drug delivery to cancer cells, different strategies utilizing accumulation
of pegylated liposomes in cancer tissue have been explored. The localization in tumor tissue
can be further enhanced by active targeting of the liposomes to specific structures in the
cancerous tissues, as the liposomes can be formulated with different surface modifications,
such as antibodies or ligands, enabling them to target specific cells or tissues (Fig. 1.11).
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Figure 1.11: Schematic representation of six liposome types. (A) Conventional liposomes and
long-circulating PEG-coated liposomes. (B) Conventional immunoliposomes and
long-circulating immunoliposomes with murine antibodies. (C) Long-circulating im-
munoliposomes with recombinant antibodies. (D) Tumor-specific ligands coupled
to conventional or long-circulating liposomes. (E) Cationic liposomes for nonspe-
cific gene-transfer. (F) Cationic and anionic liposomes with tumor-specific ligands or
human single chain antibodies for tumor-specific genetransfer (Park, 2002).
1.5.1 Antibody targeting
Long-circulating immunoliposomes can be divided into two groups according to the localiza-
tion of the antibody: coupling to the head group of the lipid or coupling to the terminus of
the PEG polymer (Fig. 1.11B). The PEG polymer does not change the binding affinity of
the antibodies to target cells in these two coupling strategies, however, the latter approach
offers a greater advantage for efficient binding due to better accessibility of the antibody
towards its target (Park, 2002).
Targeting of immunoliposomes to molecules expressed by tumor cells in the interstitial
compartment often results in internalization and intracellular release of the encapsulated
drugs. One such target is the HER2 receptor, which is a cell surface receptor overexpressed
in 20 - 30 % of breast and ovarian cancers. Park et al. (2001) demonstrated that DOX
encapsulated immunoliposomes containing anti-HER2 display increased therapeutic efficacy
towards five different HER2-overexpressing xenograft models when compared to pegylated
liposomes. They found that targeting to the HER2 receptor did not enhance accumulation
in tumor tissue. The increased anti-tumor activity was a result of more efficient intracellular
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delivery of targeted liposomes in tumor cells compared to non-targeted liposomes, which
primarily accumulated extracellularly or within macrophages.
In a similar targeting strategy, Hatakeyama et al. (2007a) used antibodies directed against
MT1-MMP, which is a key protein in angiogenesis and is expressed on neovascular cells and
on the surface of tumor cells. They demonstrated that systemic administration of DOX
encapsulated pegylated immunoliposomes into tumor-bearing mice significantly suppressed
tumor growth when compared to non-targeted liposomes. They also reported that accu-
mulation of targeted liposomes and non-targeted liposomes at the site of the tumor was
comparable, as the liposomes accumulated in tumor tissue due to the EPR effect and not as
a result of active targeting. Therefore, as for the anti-HER2 immunoliposomes, the enhanced
anti-tumor activity of MT1-MMP targeting liposomes was a result of accelerated uptake of
immunoliposomes in tumor cells.
1.5.2 Receptor targeting
Receptors overexpressed on cancer cells can also be used for targeting liposomes to tumor
tissues. The folate receptor (FR) is probably the most intensively investigated receptor target
on cancer cells. Its ligand, folic acid, is an essential vitamin in the biosynthesis of nucleotides,
hence necessary for proliferating cells. It is transported across the plasma membrane using
either the membrane-associated reduced folate carrier, which is expressed by all cells, or the
FR, which mainly is expressed on epithelial cells, activated macrophages, and tumor cells
(Lu & Low, 2002). Gabizon et al. (2010) demonstrated enhanced therapeutic efficacy of
FR-targeting liposomes in vivo. They inserted a folate-PEG-DSPE conjugate into pegylated
liposomal DOX (PLD) and analyzed the therapeutic activity of folate-targeted PLD and
non-targeted PLD in FR-expressing tumor models. They found that the therapeutic efficacy
was significantly, however, modestly increased with targeting to FR compared to PLD in all
tumor models.
The epidermal growth factor (EGF) receptor (EGF-R) is overexpressed in several human
cancers, such as lung, breast, bladder, and ovarian cancers, and has furthermore been cor-
related to advanced disease with poor prognosis (Salomon et al., 1995). Song et al. (2009)
reported identification of a novel EGF-R peptide ligand, D4 (Leu-Ala-Arg-Leu-Leu-Thr), us-
ing a computer-aided design approach. D4 peptide-PEG-conjugated liposomes demonstrated
enhanced binding and internalization into cells by endocytosis in vitro, and furthermore, they
were found to accumulate in EGF-R- expressing xenograft tumor tissues.
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1.5.3 Cationic delivery systems
For decades, cationic liposomes have been used for delivery of nucleic acids into cells in
culture, in animals, and in patients enrolled in clinical trials, due to their enhanced ability for
cell interaction compared with their neutral or anionic counterparts (Dass & Choong, 2006;
Zuhorn et al., 2007; Lila et al., 2010). Enhancement of cellular uptake as well as in vitro
cytotoxicity of cationic liposomes is normally closely associated with the charge ratio of the
cationic lipids in the formulation; higher charge ratios are generally being more toxic, due to
enhanced association with cells as a result of electrostatic interaction. Dass et al. (2002)
demonstrated that approximately 90 % of cells were viable after treatment with liposomes
containing 50 mol% positively charged lipids.
Cationic liposomes have been reported to accumulate in tumor tissue in higher degree than
neutral or anionic liposomes (Dass, 2003; Lila et al., 2010). Lila et al. (2009) investigated
the use of cationic liposomes for enhanced delivery to tumor vasculature and found that
PEG-coated cationic liposomes (11.5 ± 0.9 mV of zeta potential value) had a 2-3-fold
higher accumulation in tumor tissue compared to PEG-coated neutral liposomes (-7.2 ±
0.5 mV ). Jung et al. (2009) have developed a system of cationic liposomes complexed
with PEG for delivery of DOX to tumor tissue. They reported that association of cationic
liposomes (45.5 ± 1.1 mV) with cell membranes was increased compared to PEG-complexed
cationic liposomes (18.4 ± 0.8 mV). In vitro, their novel cationic liposomal delivery system
demonstrated cytotoxicity comparable to cationic liposomes, however, they did not observe
the enhanced efficacy in vivo where the system was comparable to Doxil.
1.6 Strategies for triggered release of drugs in tumor tissue
Site-specific targeting strategies may seem promising, however, several key issues exist: (i)
liposomes bind to the first line of target cells after accumulation in the tumor, resulting in
these liposomes obstruct the way for more liposomes to accumulate, (ii) immunoliposomes are
cleared more rapidly than non-coated liposomes, and (iii) the drug, which is internalized by
endocytosis, has to escape the endosomes before it is degraded. To enhance the therapeutic
efficacy of liposome delivered drugs, several strategies of triggered drug release in tumor
tissue have been investigated (Andresen et al., 2005).
1.6.1 Acid, heat, and light triggered release
Yatvin et al. (1980) introduced the idea to use of the acidic microenvironment found in
tumors for triggered release. This strategy, however, was not successful since it was difficult
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for liposomes to reach the sites in the tumor with the lowest pH, which was distant from the
vasculature (Helmlinger et al., 1997). Furthermore, the pH in tumors rarely declines below
pH 6.5, making it challenging to develop liposomes that are stable in the blood, with a pH
of 7.4, but disrupt in tumor tissue (Drummond et al., 2000). The acidic environment of
endosomes, which has a pH is below 5.0 (Ohkuma & Poole, 1978), has been exploited for
acid triggered release after internalization of liposomes. However, to prevent degradation
in the lysosomes, the drug has to escape the endosome before it is delivered to lysosomes
containing metabolic enzymes (Drummond et al., 2000). This strategy has led to intensive
research in acid triggered drug delivery which resulted in the use of fusogenic liposomes.
Kirpotin et al. (1996) anchored PEG in the membrane via a labile disulfide linkage to the
lipid 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE, PEG-S-S-DSPE). Liposomes
with PEG-S-S-DSPE incorporated in the membrane showed abolished pH sensitivity, how-
ever, thiolytic cleavage of the polymer restored the pH sensitive properties of the liposomal
membrane and lead to vesicle destabilization and fusion. Ishida et al. (2001b) utilized this
principle in combination with anti-CD19-targeting of circulating B-lymphoma cells and ob-
served a significantly increased therapeutic efficacy of the anti-CD19-targeted pH-sensitive
formulation compared to that of a stable long-circulating formulation of targeted liposomes.
Yatvin et al. (1978) suggested the use of mild local hyperthermia for tumor-specific drug
release. They designed liposomes consisting of 1,2-dipalmitoyl-sn-3-glycero-3-phosphocholine
(DPPC) as the main lipid component formulated with small amounts of 1,2-distearoyl-sn-
glycero-3-phosphocholine (DSPC) to adjust the main phase transition temperature to be just
above physiological temperature. These liposomes could be used for selective and controlled
drug release by induction of local hyperthermia at the site of the tumor. A formulation,
which was optimized for DOX release at 39 - 40◦C, was rationally designed in such way
that lyso-phospholipids were trapped in the liposomal membrane in the gel phase. When the
liposomes were heated above the main phase transition temperature, the lyso-phospholipids
left the bilayer, which enhanced the permeability of the liposomal membrane (Kong et al.,
2000; Needham et al., 2000). Hyperthermia as trigger of drug release has the advantage
that tumor accumulation of liposomes is enhanced as a result of increased blood flow and
microvascular permeability. However, the use of heat activated liposomes requires known
location of the tumor and that the site is accessible to local hyperthermia. Therefore,
hyperthermia cannot be used as a trigger of drug release to treat metastatic cancer, which
is the cause of death in the majority of cancer patients (Kong & Dewhirst, 1999).
Bondurant et al. (2001) initiated the use of drug release from liposomes by photopoly-
merization. They developed a novel PEG-liposome formulation containing the photosensitive
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lipid 1,2-bis[10-(20,40-hexadienoyloxy)-decanoyl]-sn-glycero-3-phosphocholine (bis-SorbPC),
which forms a cross-linked lipid network when exposed to UV-light. This resulted in drug leak-
age as the polymerization process developed defects in the bilayer. Thompson et al. (1996)
used plasmalogen photooxidation as a trigger of drug release, which relies on an increase
in membrane permeability upon photooxidative cleavage of plasmenylcholine to single-chain
surfactants (Shum et al., 2001). However, as for heat activated liposomes, this method
requires known localization of the tumor (Kong & Dewhirst, 1999).
1.6.2 Enzyme triggered release
The use of cell associated enzymes, specifically upregulated in tumor tissues, has also been
proposed for site-specific drug release (Meers, 2001). Two different approaches have been
exploited where cleavage of a lipid conjugate resulted in (i) generation of fusogenic lipids
that destabilized the liposome or (ii) unmasking fusogenic lipids or ligands to receptors
overexpressed in tumor tissue. Davis & Szoka (1998) demonstrated that liposomes sensitive
to alkaline phosphatase, consisting of cholesterol phosphate derivatives and 1,2-distearoyl-
sn-glycero-3-phosphoethanolamine (DOPE), collapsed as a result of phosphatase-catalyzed
removal of the phosphate group. This approach is validated by the findings that membrane
bound forms of phosphatase are overexpressed in tumor tissue (Milla´n & Fishman, 1995).
Most liposomal delivery systems developed to be used in cancer treatment are based on
sterically stabilized pegylated liposomes due to their ability to localize in tumor tissues.
Secretory phospholipase A2 (PLA2), which have been reported to be up-regulated in cancer-
ous tissues (Yamashita et al., 1994; Jiang et al., 2002), were utilized to achieve triggered
drug release after enzymatic cleavage (Davidsen et al., 2003; Jensen et al., 2004; Andresen
et al., 2004). The activity of PLA2 was exploited to hydrolyse a lipid-based proenhancer
formulated in the liposome, which resulted in liposome destabilization and drug release.
Lyso-phospholipids and free fatty acids that were released in the process have been demon-
strated to enhanced the permeability of membranes, potentially resulting in enhanced uptake
in cancer cells (Jespersen et al., 2012). Another group of enzymes that have been extensively
investigated for triggered release is the gelatinases. Sarkar et al. (2005) developed a strategy
for MMP-9 triggered release using pegylated liposome containing a triple-helical lipopep-
tide, which functioned as a MMP-9 substrate that after cleavage ’uncorked’ the liposomes
and released the encapsulated drug (Sarkar et al., 2008; Elegbede et al., 2008). Banerjee
et al. (2009) further reported enhanced MMP-9 sensitivity of the tripel-helical system after
optimization of the liposomal formulation. These strategies, however, result in extracellular
release of drugs, requiring that the drugs subsequent are able to cross the cell membrane to
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execute their actions on the cancer cell, as most chemotherapeutic drugs acts intracellular.
Although PEG is essential for liposomal accumulation in the tumor tissue, it may be an
obstacle in the achievement of sufficient therapeutic response due to decreasing interaction
between liposomes and the target cells (Mishra et al., 2004; Romberg et al., 2008). There-
fore, several groups have been focused on enzymatic removal of PEG after accumulation.
Hatakeyama et al. (2007b) reported a system utilizing the enzymatic activity of MMP-2 for
removal of PEG and subsequent association of liposomes with tumor cells. They developed
a PEG-peptide-lipid conjugate (PEG-Peptide-DOPE conjugate) that could be cleaved by
MMPs in cancerous tissues. However, this system depend on passive liposomal association
with cells after removal for the drug to reach its target. Terada et al. (2006) utilized the
combination of a MMP-2 cleavable lipopeptide (PEG-Peptide-DOPE) and receptor mediated
uptake to develop a hepatocellular carcinoma specific drug delivery system. The PEG coating
was removed from the liposomes in the presence of MMP-2 in cancerous tissue, revealing
a galactosylated cholesterol derivate. This molecule interacted with the asialoglycoprotein
receptor on hepatocytes resulting in enhanced internalization of liposomes.
1.7 Monocytes
1.7.1 Leukocytes
The cellular components in the blood are often referred to as ’red blood cells’, which are the
erythrocytes responsible for transportation of oxygen to the tissues and removal of CO2, and
’white blood cells’, which are the leukocytes involved in the host defense against invading
pathogens and tissue damage. The leukocytes can be divided into the following populations:
lymphocytes (T-lymphocytes, B-lymphocytes, and NK cells), granulocytes (neutrophils, ba-
sophils, and eosiniphils), and monocytes (Table 1.3, Fig. 1.12). In addition, small populations
of DCs and macrophages are also present in the blood (Ransohoff & Cardona, 2010).
These cells express an array of different surface molecules, which can be used to distinguish
them from one another. Expression of surface molecules on leukocytes is very complex, and
several markers are expressed at different levels by several cell populations, depending on their
function. The Cluster of Differentiation 16 (CD16, FcγR-III) surface antigen is for example
expressed by non-apoptopic neutrophils, monocytes, and NK lymphocytes (Passlick et al.,
1989; Moulding et al., 1999; Campbell et al., 2001). Furthermore, each cell population is
very heterogeneous consisting of cells with different functions, hence different expression of
surface molecules. Thus, for in vitro investigation of blood cells the use of a single marker to
analyze a specific cell population can be challenging and markers must be carefully chosen.
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Figure 1.12: Development of blood cells (Ransohoff & Cardona, 2010).
T- and B-lymphocytes are the major cellular components of the adaptive immune re-
sponse. T-lymphocytes are commonly characterized by CD3, which is a part of the T-cell
antigen receptor used for antigen recognition by these cells and is expressed by all cells of
the T-lymphocyte lineage (Reine´ et al., 2011). T-lymphocyte precursor cells, which originate
from bone marrow stem cells, populate the thymus during fetal life. Here they mature into
T-lymphocytes, expressing a wide variety of different receptors that recognize foreign anti-
gens but not self-antigens. These mature cells are released into the circulation where they
are involved in cell-mediated immunity (Anderson et al., 2007). B-lymphocytes, which are
characterized by CD19 expressed on all cells of the B-lymphocyte lineage except on plasma
cells (antibody-secreting B-cells), are produced in the bone marrow (Stamenkovic & Seed,
1988). They are mainly responsible for humoral immunity, involving antibodies. Following
antigen recognition, B cells become activated, proliferate, and selected cells differentiate into
plasma cells, which differentiate further into memory B-cells (Ollila & Vihinen, 2005).
NK cells, which are highly cytotoxic cells, are characterized by expression of the adhesion
molecule CD56 and lack of CD3. They do not need to recognize a specific antigen to destroy
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a target cell, but rather rely on recognition of self-molecules, upregulated in response to many
forms of cellular stress, making them potent effectors against transformed and infected cells
(da Silva & Mu¨nz, 2011). The population of CD56 cells has also been demonstrated to be
heterogeneous, and a population of NK-T lymphocytes with expression of CD3 have been
described (Campbell et al., 2001).
Eosinophils, which during homeostasis constitute 1 - 4 % of the circulating leukocyte pool,
were discovered in 1879 by Dr. Paul Ehrlich. They are found in respiratory mucosa, gastroin-
testinal tract, thymus, lymph nodes, and spleen (Bystrom et al., 2011). Eosinophils contain
large secondary granules, containing four highly basic and cytotoxic proteins: eosinophil
cationic protein, eosinophil-derived neurotoxin, eosinophilperoxidase, and major basic protein
(Rohrbach et al., 1990). Their roles in homeostasis and disease still remains to be eluci-
dated (Bystrom et al., 2011). Basophils, which constitute less than 1 % of leukocytes, were
first described in 1891 by Dr. Paul Ehrlich (Fredericks & Moloney, 1959). Activated ba-
sophils release histamine, IL-3, and IL-4 involved in induction of Th2 differentiation of CD4+
T-lymphocytes (Voehringer, 2011a,b).
The neutrophil granulocytes, which constitute more than 50 % of all leukocytes in pe-
ripheral human blood (Bain & England, 1975), are phagocytosing cells referred to as poly-
morphonuclear phagocytes due to the special morphology of the multi-lobed nucleus. They
express CD15, involved in phagocytosis (Kucukkaya et al., 2001), and CD16, however, they
lose expression of CD16 when undergoing apoptosis (Moulding et al., 1999). At the onset
of infection or inflammation, cells of the innate immune system recognize the intruders or
tissue damage and are responsible for initiating an appropriate immune response including
recruitment of immune cells to sites of injury. Leukocyte infiltration is triggered by release
of inflammatory agents, such as histamine, cytokines (e.g. tumor necrosis factor (TNF)-α),
chemokines (e.g. CCL2), and lipid mediators (e.g. eicosanoids), from cells residing in the
tissues. The first cell type to react the site of injury is the neutrophils, which phagocytose
bacteria and foreign cells as well as damaged and dead host cells. The neutrophils are in-
volved in recruitment of monocytes to the inflammatory site, and are cleared as the numbers
of monocytes and macrophages increase (Liddiard et al., 2011). Neutrophils in the circulation
have a short half life due to commitment into an apoptotic pathway, which can be delayed
by cytokines, such as granulocyte-macrophage colony-stimulating factor, IFN-γ, IL-2, and
IL-6, released by cells in inflammatory tissues (Moulding et al., 1999).
Monocytes, macrophages, and DCs are commonly referred to as mononuclear phagocytes,
as one of their main roles is phagocytosing pathogens, apoptotic host cells, and foreign par-
ticles (Ransohoff & Cardona, 2010). This occurs either through opsonin receptor-dependent
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mechanisms (complement- and Fc-receptors, described in section 1.4.1) or opsonin receptor-
independent mechanisms (lectin-receptors, scavenger receptors, stearylamine receptors, de-
scribed in section 1.4.3) (Kelly et al., 2011). In addition, they are involved in cytokine
production. Two subpopulations of DCs have been isolated from the blood (O’Doherty
et al., 1994), which are involved in recognition of pathogens in the blood and non-lymphoid
tissues leading to T-cell activation through antigen presentation and cytokine production
(Ishimoto et al., 2008).
Monocytes and macrophages both express the scavenger receptor CD14, which has been
recognized as the major receptor for LPS. CD14 dimerize with the Toll-like receptor (TLR)
4 and interact with MD-2. TLRs comprise a family of type I transmembrane receptors,
characterized by an intracellular Toll/IL-1 receptor domain and an extracellular leucine-rich
repeat domain. The result of TLR activation is translocation of transcription factors to the
nucleus and activation of transcription of proinflammatory cytokines, such as TNF-α, IL-1β,
IL-6, and IL-8, and other proinflammatory factors (Means et al., 2000; Medzhitov, 2001;
Triantafilou & Triantafilou, 2002).
1.7.2 Monocytes
Monocytes, which represent about 10 % of all leukocytes in human blood, are a heterogeneous
population of cells with regard to size and shape. They have, however, common morphological
features such as irregular cell shape, a high cytoplasm-to-nucleus ratio, a kidney-shaped
nucleus, and cytoplasmic vesicles. They express a wide array of scavenger receptors on their
surface involved in recognition of PAMPs. Upon stimulation, monocytes can produce large
quantities of ROS, complement factors (e.g. C3 and factor B), and VEGF (Auffray et al.,
2009). Monocytes circulate in the blood and migrate into tissues in respond to infection or
inflammation. Migration into inflammatory sites is governed by chemokines, such as CCL2,
which signal through CCR2, and CX3CL1, which signal through CX3CR1. Furthermore, they
play an important role in the immune defense through production of cytokines, including
TNF-α, IL-1β, IL-10, and IL-6 (Auffray et al., 2009; Commins et al., 2010).
It has long been recognized that monocytes are a heterogen population of cells with differ-
ent functions (Muller, 2001). In the early 1980s it was found that monocytes could be divided
into two populations based on size and density: a major population consisting of large mono-
cytes with high myeloperoxidase and phagocytic activity, which released high concentrations
of superoxide, and a minor population of small monocytes with low myeloperoxidase activity,
which released high levels of IL-1 (Figdor et al., 1982; Akiyama et al., 1983, 1985). The
existence of these populations was later confirmed and monocytes were characterized on ba-
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sis of their expression of CD14 and CD16: the ’conventional’ CD14+CD16− monocytes and
the pro-inflammatory CD14+CD16+ monocytes (Passlick et al., 1989; Belge et al., 2002).
CD14+CD16− monocytes, which represent 80 % to 90 % of blood monocytes, were reported
to have high phagocytic activity, but low cytokine production. In vitro, they produced IL-10
in response to LPS. These monocytes were found to express high levels of CCR2 and low
levels of CX3CR1 (Auffray et al., 2009). In response to LPS the CD14+CD16+ monocytes
produced TNF-α, which regulates the immune response by activating other cells for enhanced
proliferation, receptor expression, and migration as well as stimulating production of other
cytokines, thus, they were called proinflammatory monocytes. These cells do not express
CCR2, but express high levels of CX3CR1 (Belge et al., 2002; Ancuta et al., 2003). It was
suggested by Ziegler-Heitbrock (2007) that the CD16+ monocytes were more mature than
the CD14+CD16− monocytes, since their surface antigens resembled the pattern observed
in mature tissue macrophages.
However, monocyte biology proved to be more complex, as it was demonstrated by
Skrzeczynska-Moncznik et al. (2008) that the population of CD16+ monocytes consisted of
at least two different populations with distinct functions: CD14+CD16+ and CD14dimCD16+
(Table 1.3). Cros et al. (2010) have conducted a large study of monocytes in human blood,
where they analyzed the cytokine production in these three subsets of monocytes (Table 1.3).
They demonstrated that CD14dimCD16+ monocytes, which have a low cytokine production
and were suggested to be anti-inflammatory of nature, are ’patrolling’ cells that migrate
through capillaries, where they detect virally infected or damaged cells. These findings are
in line with a previous study demonstrating that CD16+ monocytes adhered to endothelial
cells better than CD14+ monocytes in vitro due to high expression of the chemokine receptor
CX3CR1 (Ancuta et al., 2003). In addition, Cros et al. (2010) found that the population
of CD14+CD16− monocytes produced ROS, IL-6, IL-8, and CCL2 and the population of
CD14+CD16+ monocytes produced TNF-α and IL-1β. Hence, the two CD14+ populations
were both characterized as proinflammatory cells. Furthermore, the phagocytic activity of
these populations was high, whereas the CD14dimCD16+ monocytes had low activity.
1.7.3 Targeting liposomes to monocytes
The interactions of different liposome formulations with blood cells have been investigated
in order to understand the fate of liposomes after I.V. administration. Finkelstein et al.
(1981) investigated the interaction in vitro of negatively charged multilamellar liposomes
consisting of egg phosphatidylcholine, anionic dicetyl phosphate, and cholesterol (70:20:10)
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Population Subpopulation CD expression Function & cytokine production
Lymphocytes T-lymphocytes CD3 Antigen mediated immunity
B-lymphocytes CD19 Antibody mediated immunity
NK cells CD56 Destruction of damaged cells through
recognition of self-molecules
Granulocytes Eosinophils Contain cytotoxic proteins
Basophils Histamine, IL-3, and IL-4
Neutrophils CD15/CD16* Phagocytosis
Recruitment of immune cells
Monocytes CD14+CD16− CD14 Phagocytosing, pro-inflammatory cells
ROS, IL-6, IL-8, and CCL2
CD14+CD16+ CD14/CD16 Phagocytosing, pro-inflammatory cells
TNF-α and IL-1β
CD14dimCD16+ CD16 Patrolling, anti-inflammatory cells
Table 1.3: Simplified overview of leukocytes in human blood. *Non-apoptotic neutrophils.
with human leukocytes in heparinized whole blood. The uptake was analyzed based on the
cellular association of 3H-labeled cholesterol as a marker of the lipid phase and 14C-labeled
inulin as a marker of the aqueous phase. They found that the uptake of liposomes by human
leukocytes was enhanced in the presence of serum or when liposomes were precoated with a
high molecular weight fraction of heat-aggregated immunoglobulin G. They furthermore used
ultrastructural cytochemistry to demonstrate greater uptake of liposomes in monocytes than
in neutrophils and lymphocytes. Constantinescu et al. (2003) analyzed the uptake of nega-
tively charged liposomes consisting of DSPE-PEG2000, DPPC, and cholesterol (3.5:66.5:30)
in whole blood in vitro. 5 µL whole blood was mixed with 2 - 50 µL liposomes (1mM lipid)
in a total volume of 100 µL (HEPES buffer) and incubated for 2 hour at room temperature,
after which they observed high uptake in 81 % of leukocytes.
The early studies of interaction between liposomes and blood cells were focused on avoiding
uptake by cells of the MPS, whereas specific targeting to the MPS gained increased interest in
later studies. Targeting of liposomes to monocytes can be achieved by (i) changing the lipid
composition to control the physiochemical properties of liposomes and (ii) addition of sur-
face molecules, such as peptides, antibodies, polysaccharides, glycolipids, glycoproteins, and
lectins, recognized by these cells (Drummond et al., 1999; Kelly et al., 2011). Epstein-Barash
et al. (2010) recently reported a large study, where they compared the effect of liposome
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size and charge on the bioactivity of liposomal bisphosphonates. They analyzed liposome
association with several cell types in vitro in the presence of 10 % fetal calf serum, such as
the monocyte/macrophage cell lines THP-1, J774, and RAW 264, and primary cells, such as
monocytes, neutrophils, kupffer cells, endothelial cells, and smooth muscle cells. They also
analyzed the in vivo effect of encapsulated drugs and cellular association. The liposomes used
in the study ranged in size from 50 to 800 nm in diameter and were formulated with neutrally,
positively, or negatively charge lipids. From this study, it was concluded that small (85 nm)
negatively charged liposomes composed of DSPC, distearoylphophatidylglycerol (DSPG), and
cholesterol (3:1:2) were optimal for targeting cells of the MPS. Furthermore, they found that
large and positively charged liposomes, containing positively charged dimethyldioctadecyl
ammonium bromide (DODAB), induced cytokine activation and were cytotoxic.
These findings are consistent with previously reported studies of the association of nega-
tively charged liposomes with cells of the MPS. Lee et al. (1993) investigated the interaction
of neutral liposomes, composed of phosphatidylcholine (PC) and cholesterol (2:1), vs. neg-
atively charged liposomes, composed of PS, PC, and cholesterol (1:1:1), on isolated human
monocytes cultured in suspension or as adherent cells in vitro. They found that uptake of
negatively charged liposomes depended on the maturation state of the monocytes. When the
cells differentiated into macrophages the uptake of negatively charged liposomes increased
5-fold, whereas uptake of neutral liposomes remained constant, which was also observed for
the uptake of both formulations in monocytes cultured in suspension.
Several groups have attempted to utilize the uptake of negatively charged liposomes by
monocytes for targeting the brain, which can be difficult to reach with drugs due to its
protection by the blood-brain barrier. Jain et al. (2003) suggested the use of negatively
charged and RGD (small peptide consisting of Arg-Gly-Asp) coated magnetic liposomes for
monocyte/neutrophil-mediated delivery of inflammatory drugs to the brain. The liposomes
were formulated of soya PC, cholesterol, and PS. The liposomes, which had a size of ap-
proximately 1 µm, were preferentially taken up by neutrophils and monocytes, whereas the
uptake by the liver macrophages was significantly decreased. They demonstrated enhanced
accumulation of this formulation in the brain compared with non-magnetic RGD coated li-
posomes. Afergan et al. (2008) were also interested in delivery of drugs to the brain, and
found that negatively charged liposomes composed of DSPC, DSPG, and cholesterol (3:1:2),
with a size of 169.32 ± 36.32 nm and a zeta potential of - 29± 1.9 mV, associated with
monocytes and were subsequently able to deliver serotonin to cells in the brain.
Karathanasis et al. (2009) used another approach for targeting monocytes. They for-
mulated 122 - 128 nm liposomes with a specific positively charged peptide, GGPNLTGRW
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(GGP), anchored in the membrane and analyzed the association of liposomes with blood cells.
Liposome preparations were added to 200 µL blood, which was anti-coagulated with sodium
citrate, for 3 hour at 37 ◦C with gentle rocking. It was found that they could specifically
target neutrophils and monocytes by optimizing the number of targeting peptide ligands on
the surface. By increasing the density of the peptide from 250 to 500 molecules on each lipo-
some they could enhance the binding to neutrophils and monocytes. The peptide contained
one positive charge, however, they demonstrated that uptake depended on the sequence of
the peptide and not the positive charge, since a non targeting control peptide with same pos-
itive charge did not enhance uptake of liposomes. Schenk et al. (2011) used heparin-binding
epidermal growth factor (HB-EGF), which is a membrane associated protein expressed by
several cell types, including cells of the hematopoietic lineage. Diphtheria toxin (DT) is
internalized by binding to HB-EGF, thus cells expressing HB-EGF can be targeted with a
non-toxic variant of DT, called cross-reacting material 197. They reported efficient targeting
to monocytes and DCs in purified human peripheral blood mononuclear cells (PBMCs).
Leuschner et al. (2011) have recently published a study of siRNA silencing in inflammatory
monocytes in mice, using a carrier previously identified in high-throughput in vitro screening
of compounds resulting in identification of a particle containing a synthetic lipid (C12-200
lipid) with efficient cell delivery and knockdown abilities (Love et al., 2010). They encap-
sulated chemokine receptor CCR2 siRNA in liposomes containing C12-200 lipid to inhibit
localization of inflammatory monocytes to injured tissue, since migration of these cells into
tissues depends on the CCR2. They reported rapid blood clearance of this nanoparticle,
which accumulated in spleen and bone marrow, and localized to monocytes when adminis-
tered systemically in mice. Treatment reduced the number of inflammatory monocytes in
atherosclerotic plaques, reduced infarct size after coronary artery occlusion, prolonged normo-
glycemia in diabetic mice after pancreatic islet transplantation, and resulted in reduced tumor
volumes and lower numbers of tumor-associated macrophages (Leuschner et al., 2011).
1.7.4 Immune-suppressive liposomes
Specific targeting of liposome encapsulated anti-inflammatory drugs to monocytes and macro-
phages is highly attractive due to severe side effects associated with long-term administration
of e.g. glucocorticosteroids (GCs) used in the treatment of inflammatory diseases, such as
atherosclerosis and rheumatoid arthritis. Since these drugs have low bioavailability, high and
frequent doses have to be administered to reach pharmacologically active drug levels at the
site of inflammation resulting in a considerable number of side effects, including hypertension,
diabetes, sleep apnea, osteoporosis, myopathy, and disorders of coagulation and fibrinolysis
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(Zhou & Cidlowski, 2005; Weinstein, 2011; Peppa et al., 2011). Thus, liposome formulations
with the GC dexamethasone (DxM) are being investigated for clinical use.
Atherosclerosis is a progressive, inflammatory disease with a pattern similar to that of
chronic inflammation, where monocytes and macrophages play a major role through pro-
duction of proinflammatory cytokines, especially IL-6 (Gabay, 2006; Woollard & Geissmann,
2010). Chono et al. (2005) have reported that liposome encapsulated DxM phosphate (DxM-
P) enhances as well as prolongs the anti-inflammatory effect compared with the free drug
in an atherosclerotic mouse model. They used negatively charged liposomes consisting of
egg phosphatidylcholine, cholesterol, and charged dicetylphosphate (70:20:10 mol %), con-
taining 1 mg/mL DxM-P, with a mean size of approximately 70, 200, and 500 nm. They
found that the serum concentration of liposomes with a size of 70 nm was higher than those
of 200 or 500 nm, indicating that the small liposomes could avoid the MPS. This finding
was consistent with previously reported studies of liposome uptake (Juliano & Stamp, 1975).
Chono et al. (2005) suggested that the higher efficacy of the 200 nm liposomes compared
to the two other formulations was a result of liposomal size and permeability of the blood
vessels. The 500 mm liposomes were recognized by macrophages, but were too large to pass
the vascular wall, whereas the 70 nm liposomes could pass the wall, but was not recognized
by macrophages.
Rheumatoid arthritis is a systemic disorder characterized by chronic inflammation of joints
with accumulation of macrophages, T- and B-lymphocytes within the synovium, resulting in
joint destruction and pain (Kinne et al., 2007; Schmutz et al., 2010). Rheumatoid arthritis is
treated with disease-modifying anti-rheumatic drugs (DMARDs), antibodies aganist TNF-α,
and GCs (Thalayasingam & Isaacs, 2011). The latter have unequaled efficacy, but is unfortu-
nately also associated with severe side effects after long-term administration. Thus, selective
delivery of GCs to the joints could significantly improve current treatment of rheumatoid
arthritis (Metselaar & Storm, 2005; McInnes & Schett, 2011). Anderson et al. (2010) re-
ported enhanced and prolonged anti-inflammatory effect of liposome encapsulated DxM-P
compared with the free drug in a rat model of rheumatoid arthritis. Neutral liposomes con-
sisting of 1,2-dipalmitoyl-sn-glycero-3- phosphocholine (DPPC), 1,2-dipalmitoyl-sn-glycero-
3-(phosphor-rac-(1-glycerol))(sodium salt) (DPPG) and cholesterol (50:10:40 mol %) were
formulated with 0.5 mg/mL DxM-P. The liposomes, which had a size of 283-310 nm, were
superior to free DxM-P in both short-term and long-term treatment. They found that ad-
ministration of one low dose (1 x 0.1 mg/kg) liposomal DxM-P were equally efficient as three
high doses (3 x 1mg/kg) free DxM-P, indicating the possibility to obtain therapeutic efficacy
with less frequent and/or lower doses of drug.
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Figure 1.13: Anti-inflammatory actions of glucocorticosteroids (GCs). GCs cross the cell mem-
brane and bind to the intracellular glucocorticoid receptor (GR), which then translo-
cates to the nucleus. Many genes contain glucocorticosteroid response elements
(GREs) in their promoters. Transactivation leads to transcription of genes encod-
ing anti-inflammatory mediators, such as interleukin-10 (IL-10) and the inhibitor of
nuclear factor-κB (IκBα), whereas transrepression switch off the expression of inflam-
matory genes by interaction with transcription factors activated by pro-inflammatory
signals. RNA pol II: RNA polymerase II (Holgate & Polosa, 2008).
1.7.5 MPS-targeting liposomal formulation in the clinic
Immunostimulating liposomes have also been investigated extensively and several liposomal
formulations are already approved for clinical use (Metselaar & Storm, 2005; Zolnik et al.,
2010). The immunostimulating liposomal formulation Mepact R© (Takeda Pharmaceutical
Company Limited, Osaka, Japan), which was approved by FDA in 2009, utilizes the ability
of the innate immune system to recognize conserved PAMPs, such as PG that is the major
structural component in the cell wall of gram positive bacteria, where it constitutes 30 - 70 %
of the entire wall. Gram negative bacteria contain less than 10 % PG (Schleifer & Kandler,
1972). The innate immune system recognizing specific fragments of bacterial PG, also known
as muropeptides, which are sensed by intracelular nucleotide-binding oligomerization domain
1 (NOD1) and NOD2. One of these muropeptides, muramyl dipeptide (MDP) that mediates
cell signaling by NOD2, has been demonstrated to synergize with LPS to induce secretion of
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proinflammatory cytokines (Fritz et al., 2005; Geddes et al., 2009). Mepact R© contains the
NOD2 receptor agonist mifamurtide (MTP-PE), which is a synthetic molecule derived from
MDP. It is used in addition to chemotherapy for treatment of pediatric osteosarcoma, where
it has been demonstrated to increase the overall survival significantly (Nardin et al., 2006;
Kager et al., 2010; Ando et al., 2011).
AmBisome R© (Gilead Sciences, Inc, Foster City, CA, USA) was approved by FDA in 2000.
It is a liposomal formulation containing the broad-spectrum antifungal drug Amphotericin B,
which is the most effective drug for treatment of life-threatening fungal infections. The use
of Amphotericin B is limited by infusion-related toxicity, resulting in fever and chills due to
secretion of proinflammatory cytokine by innate immune cells (Holeman & Einstein, 1963;
Sau et al., 2003). AmBisome R© has been suggested to associate with cells of the MPS and
thereby transferred to the site of infection (Walsh et al., 1998). Sau et al. (2003) investigated
the mechanism of amphotericin B and found that it promotes production of inflammatory
cytokines through a toll-like receptor- and CD14-dependent mechanism. Encapsulation of
amphotericin B has been shown to reduce nephrotoxicity, associated with the free drug, while
retaining therapeutic activity (Walsh et al., 1998; Adler-Moore & Proffitt, 2008).
A novel liposomal formulation of amphotericin B is currently being developed. Banerjee
et al. (2008) demonstrated that encapsulation of amphotericin B in stearylamine (SA)-bearing
cationic liposomes could be used for treatment of visceral leishmaniasis in hamster. Severe
infections, such as visceral leishmaniasis that is caused by the parasite Leishmania donovani
resulting in parasitization of liver, spleen, and bone marrow, can be difficult to treat and is
therefore life-threatening.
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Aim of study
The objective of this project was to design a novel liposomal drug delivery system for can-
cer treatment, where enhanced MMP-2 activity in cancerous tissues was exploited as a site
specific trigger of controlled drug release. To succeed, the MMP-2 sensitive drug delivery
system should have the following features :
1) The liposomes should be long-circulating to ensure accumulation in cancerous tissues.
2) The MMP-activated trigger system should result in drug release at specific sites.
3) The liposomes should have enhanced cell interaction after activation to enable delivery
of drug directly into the cancer cells.
To achieve this, close collaboration between several scientific fields was essential, as the phys-
iochemical properties of the liposomes, the synthesis of the trigger mechanism, and biological
evaluation of the performance of the drug delivery system was equally important aspects of
the developing process. The following aspects had to be elucidated on the biological part:
1) Analysis of expression and activity of MMP-2 in different cancer cell lines as well as in
healthy and cancerous tissues.
2) Evaluation of the trigger mechanism with recombinant enzymes.
3) Develop model systems for in vitro and in vivo evaluation of liposome activation.
4) Investigation of the interaction with phagosytosing cell populations in human blood.
Project outline
The drug delivery system was designed to consist of long-circulating liposomes as a result of
a novel lipopeptide-PEG conjugate anchored in the lipid bilayer (Fig. 1.14A). The PEG chain
was conjugated to a lipopeptide containing a MMP-2 substrate sequence that had negatively
charged amino acids close to the PEG chain (Fig. 1.14B). As a result of positively charged
lipids formulated in the liposome, the overall charge of the was neutral. After removal of
PEG in the presence of MMP-2 in cancerous tissues the liposomes would have a positive
charge (Fig. 1.15A), resulting in enhanced interaction with cell membranes and release of
the encapsulated drug into the cancer cells (Fig. 1.15B).
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Figure 1.14: The design of the drug delivery system. (A) The liposome with PEG on the surface.
(B) The PEG chain conjugated to a lipid by a MMP-2 cleavable peptide sequence.
The peptide is negatively charged close to the PEG chain.
Figure 1.15: Activation of the drug delivery system. (A) In the presence of MMP-2 the PEG
chains will be removed as a result of cleavage of the substrate sequence. (B) After
activation, the liposomes are positively charged and will interact with cell membranes
delivering the drugs into the cancer cells.
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2.1 Abstract
Development of novel strategies for delivery of chemotherapeutics have gained increased
attention due to severe side effects associated with drug distribution to healthy tissues. Here,
we report a novel liposomal drug delivery system that exploits the increased MMP-2 activity
in tumor tissue as a site specific trigger for liposome activation and controlled drug release.
A MMP-2 substrate peptide was conjugated with stearic acid and PEG, resulting in a novel
MMP-2-cleavable lipopeptide-PEG conjugate (stearic acid-GIPVS-LRSGGDD-PEG, RJ111).
The PEG coating, which had a negative charge, was removed by MMP-2 activity in tumor
tissue achieving cationic liposomes, as a result of 1,2-dioleoyl-3-trimethylammonium-propane
(DOTAP) in the liposomal membrane. Enzymatic activation resulted in enhanced association
of liposomes with cancer cells in vitro and furthermore, evaluations of the association of
liposomes with phagocytosing cells in human blood revealed that the formulation was not
recognized by these cells without prior enzymatic activation. Encapsulation of oxaliplatin
resulted in significant increased toxicity compared with the free drug in vitro. High MMP-2
expression and activity was observed in human clinical samples and patient-derived colon
cancer xenografts in mice, supporting the use of MMP-2 as a trigger for liposomal activation
in tumor tissue. This drug delivery strategy results in enhanced bioavailability of delivered
drugs in tumor tissues while decreasing side effects in healthy tissues.
2.2 Introduction
To enhance efficacy of cancer treatment, tumor specific drug delivery strategies leading to
enhanced accumulation of drug at the site of the tumor, has gained increased attention.
Doxil, DOX encapsulated in Stealth R© liposomes, was the first liposomal formulation to be
approved by FDA for clinical use in 1995 (Gabizon, 2001a). Liposomal encapsulation of
DOX significantly reduced cardiotoxicity associated with the free drug, by changing drug
pharmacokinetics and biodistribution (Working et al., 1999). Stealth R© liposomes are a passive
drug delivery system that exploits the differences in permeability of blood vessels in cancerous
and healthy tissues and after liposomal accumulation, the system relies on passive diffusion
for the drug to reach its target (Gabizon, 2001b). The release of DOX after accumulation
in the tumor tissue, which is assumed to be a result of the active loading of this drug, are
not observed with e.g. cisplatin used in the SPI-077 formulation, which is passively loaded
(Andresen et al., 2005). Therefore, to enhance specific drug delivery of various drugs to
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cancer cells, different strategies utilizing the accumulation of pegylated liposomes in cancer
tissue have been explored. These include specific binding of liposomes to tumor cells mediated
by antibodies (Park et al., 2001; Hatakeyama et al., 2007a), liposome endocytosis mediated
by ligands for receptors expressed in high levels on tumor cells (Song et al., 2009; Suzuki
et al., 2008; Ishida et al., 2001a; Gabizon et al., 2010), and cationic liposomes for increased
association of liposomes with cell membranes (Lila et al., 2009; Jung et al., 2009).
Although PEG is essential for liposomal accumulation in the tumor tissue, it may be an
obstacle in the achievement of a sufficient therapeutic response due to decreasing interaction
between liposomes and the target cells (Romberg et al., 2008). Thus, attempts have been
made to increase the therapeutic efficacy of pegylated liposomes by removing the PEG coating
after localization at the target site (Terada et al., 2006; Hatakeyama et al., 2007b; Jung
et al., 2009). Targeting of drugs to specific sites of the body, by increased understanding of
structure and function of the target tissue, has gained increased attention in the last decades
in an attempt to achieve controlled drug release. Therefore, the physiological changes of
cancerous tissues have been exploited in the search of a strategy to enhance the bioavailability
of chemotherapeutics in the diseased tissue. Recently, several attempts have been made to
develop novel delivery strategies, where the carriers are degraded by enzymes, such as the
gelatinases, which have been associated with cancer progression and metastasis for decades
(Stetler-Stevenson, 1990; Woessner, 1991; Egeblad & Werb, 2002).
Hatakeyama et al. (2007b) reported a system utilizing the enzymatic activity of MMP-2 for
removal of PEG and subsequently observed enhanced association of liposomes with HT1080
cells. However, as with the Stealth R© liposomes, this system relies on passive association of
liposomes with cells for the drug to reach its target. Sarkar et al. (2005) have developed a
strategy for MMP-9 triggered release of drugs from liposomes. They used pegylated liposome
containing a triple-helical lipopeptide as a MMP-9 substrate that after cleavage ’uncork’ the
liposomes resulting in drug release (Sarkar et al., 2008; Elegbede et al., 2008). This was a
major improvement as the drug would be actively released in the tissues by specific enzymatic
activity. Banerjee et al. (2009) further reported enhanced MMP-9 sensitivity of the triple-
helical system after optimization of the liposomal formulation, demonstrating enhanced tissue
specificity by changing physiochemical properties of the delivery system.
However, a major limitation of these delivery strategies was that the encapsulated drug
was released in the extracellular space. If the delivered drugs executed their actions intracel-
lularly, which is the case with most chemotherapeutics, the therapeutic efficacy would rely
on their ability to cross the cell membrane after release, potentially resulting in decreased
bioavailability end thereby low drug efficiency. Terada et al. (2006) utilized the combination
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of a MMP-2 cleavable lipopeptide and receptor mediated uptake to develop a hepatocellular
carcinoma specific drug delivery system. The PEG coating was removed from the liposomes
in the presence of MMP-2 in cancerous tissue, revealing galactosylated cholesterol derivate.
This molecule interacted with the asialoglycoprotein receptor on hepatocytes resulting in
internalization of liposomes. This system demonstrated the strength in rationally designed
delivery strategies based on biological knowledge of the target tissue.
The continuous search for new and more advanced strategies for delivery of chemother-
apeutics, exploiting physiological changes in the tumor tissue to enhance targeted delivery
is of great importance. Gelatinase activated liposomes have become promising candidates
for specific delivery of drugs in cancer treatment, since they potentially, without affecting
healthy tissues significantly, accumulate in cancerous tissues and release the drug due to tis-
sue specific enzymatic activity. Here we describe the rational design and biological studies of
a novel MMP-2 activated liposomal drug delivery system, resulting in triggered drug release
specifically into the cells of cancerous tissue.
2.3 Materials and methods
2.3.1 Materials
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-dioleoyl-3-trimethylammonium-
propane (DOTAP), 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1’-rac-glycerol) (POPG) and
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]
(DOPE-PEG2000) were obtained from Avanti Polar Lipids (Alabaster, AL, USA) and used
without further purification. Bovine serum albumin (BSA) was obtained from Biofac A/S
(Kastrup, DK). Cell culture reagents were purchased from BioWittaker (Lonza, Verviers,
Belgium) unless otherwise specified.
2.3.2 High-performance liquid chromatography (HPLC)
100 µL samples containing peptide (0.2mg/mL) and enzymes (5 mg/mL) were incubated for
24 h at 37◦C. The separation was performed with a SMART microchromatography system
(GE Healthcare, UK). Samples were separated by gradient elution on a Gemini C18 column
from Phenomenex, 5 µm particle size, 110 Angstrom pore size (dimensions 250 x 2.0 mm,
Phenomenex cat. no. OOG-4435-BO) with a flow rate of 0.1 mL/min. The eluents were (A)
water and (B) acetonitrile. Gradient: 40 to 70 % B in 40 min. 50µL enzyme enzyme-peptid
mixture was injected. UV detection was performed at 214 nm.
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2.3.3 Culture of cancer cell lines in vitro
HT1080 (fibrosarcoma cell line) and MBA-MD-435 (breast carcinoma cell line) were gener-
ously provided by Dr. Iduna Fichtner (Max Delbru¨ck Center for Molecular Medicine Robert,
Berlin-Buch). LOX IMVI (human amelanotic melanoma) and 786-0 (human renal cell car-
cinoma) were obtained from the National Cancer Institute (NCI-Frederick Cancer Research
and Development center, Frederick, USA). Cells were cultured in RPMI-1640 supplemented
with 10 % (v/v) heat-inactivated fetal bovine serum (FBS), 2 mM glutamine, 100 U/mL
penicillin, and 100 µg/mL streptomycin. Cells were incubated at 37◦C in a humidified at-
mosphere in the presence of 5 % CO2. Cells were passaged every 4 - 5 day, when 80-90
% confluent. Cells were photographed using a phase contrast microscope (Nikon Eclipse
TS100, Nikon Instruments Inc., Melville, NY, USA).
2.3.4 Phorbol ester and Concanavalin A stimulation
For stimulation experiments adherent cells were cultured until confluency and treated with
50 ng/mL Phorbol 12-myristate 13-acetate (PMA, Sigma) or 20 µg/mL Concanavalin A
(ConA, Sigma). They were cultured for 24 h in serum-free medium at 37◦C in a humidified
atmosphere in the presence of 5 % CO2. Following treatment, conditioned medium (CM)
was collected, centrifuged at 1000 g for 15 min at 4◦C, and stored at -80◦C. Cells were lysed
as described by Oh et al. (1999). Lysis buffer containing 1 % Triton X-100, 500 mM Tris-HCl
(pH 7.6), 200 mM NaCl and 10 mM CaCl2 were added to the cells, which were mechanical
removed from the plate. Cells were subsequent incubated for 1 h at 4◦C with the addition
of 0.2 % sodium n-dodecyl sulfate (SDS), centrifuged at 20000 g for 20 min at 4◦C, and
stored at -80◦C until analyzed by gelatin zymography.
2.3.5 Gelatin zymography
Gelatin zymography was performed in precast 10 % polyacrylamide minigels containing gelatin
(0.1 % , Invitrogen). Samples were run in non-reducing conditions without prior boiling.
Recombinant MMP-2 and MMP-9 (PF037 and PF038, respectively, MERCK) were used as
controls. After electrophoresis, gels were washed in Zymogram Renaturing Buffer (Invitrogen)
for 30 min at room temperature with gentle agitation to allow proteins to renature. The
gels were then incubated in Zymogram Developing Buffer (Invitrogen) for 30 min at room
temperature. Subsequently, fresh Zymogram Developing Buffer was added and the gels were
incubated for 16 h at 37◦C. The zymograms were stained with Coomassie Blue (Invitrogen)
for 24 h and destained in water, before scanned using a HP Jetscan 4890.
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2.3.6 Homogenization of murine tissues
Mouse tissue and samples from tumors on mice were homogenized as described by Corthorn
et al. (2007). Liver, kidney, spleen, heart, and lungs were collected from mice after they were
sacrificed. The organs were quick-frozen in liquid nitrogen and stored at -80 C. After thawing
the tissues, they were cut into smaller pieces, weighted and 10 x lysis buffer containing 1
% Triton X-100, 500 mM Tris-HCl (pH 7.6), 200 mM NaCl, 10 mM CaCl2 were added (1
µL/mg tissue). The tissue were cut into small pieces and homogenized by blending. MMP-2
was added to one of two tubes as control (0.2 ng/µL). Samples were centrifuged at 4000 g
for 20 min at 4◦C. 0.2 % SDS was added and the samples were incubated for 1 h at 4◦C,
centrifuged at 20000 g for 30 min at 4◦C, and stored at -80◦C until analyzed by gelatin
zymography.
2.3.7 Homogenization of human clinical tumor samples
Human clinical tissue samples were generously provided by Estrid Høgdall (Danish Biobank,
Herlev Hospital at Dept of Pathology, Herlev University Hospital). Tumors were collected
from patients during surgery. The tissue were quick-frozen and stored at -80◦C. After thawing
tissues, they were cut into smaller pieces, weighted and 10 x lysis buffer containing 1 %
Triton X-100, 500 mM Tris-HCl (pH 7.6), 200 mM NaCl, 10 mM CaCl2 were added (1
µL/mg tissue). The tissue were cut into small pieces and homogenized by the FastPrep
system (setting 6.5 for 2 x 30 sec). Samples were centrifuged at 4000 g for 20 min at 4◦C.
0.2 % SDS was added and the samples were incubated for 1 h at 4◦C, centrifuged at 20000
g for 30 min at 4◦C, and stored at -80◦C until analyzed by gelatin zymography.
2.3.8 Pro-MMP-2 activation with amino-phenyl mercuric acetate (APMA)
Pro-MMP-2 (0.2 ng/µL) was incubated with 1 mM APMA in activation buffer containing
50 mM Tris-HCl (pH 7.6), 1.5 mM NaCl, 0.5 mM CaCl2 and 1 µM ZnCl2 for up to 2 h.
Samples were denatured by SDS and analyzed by gelatine zymography. 1 ng enzyme was
loaded in each lane.
2.3.9 Cell proliferation assay
Cell viability was assessed based on the ability of the cells to convert a tetrazolium reagent,
2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide
(XTT, Sigma, St. Louis, USA), into a water-soluble formazan product. 104 cells were plated
in each well in 100 µL culture medium containing 0-12.5 µM APMA or 0-50 µM oxaliplatin
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on a 96-well microtitre plate and incubated for up to 4 h at 37◦C. Cells were washed and
cultured in fresh medium for 72 h. XTT labelling mixture (20 µL) was added and cells
were further incubated for 2 h. The absorbance of the samples was measured at 450 nm
subtracted the absorbance at 690 nm as recommended by the manufacturer using an Infinite
200 microplate reader (Tecan, Ma¨nnedorf, Switzerland).
2.3.10 Stabilization of active MMP-2 by gelatin and BSA
Active MMP-2 (aMMP-2, MERCK, PF023, 0.5 µg/mL) was incubated with 0.25 mg/mL
gelatin (prepared by heating type I collagen (rat tail, BD) at 60◦C for 30 min) or 0.5 % BSA
for up to 20 h at 37◦C. Samples were denatured by SDS and analyzed by gelatin zymography.
1 ng enzyme was loaded in each lane.
2.3.11 Effect of glycerol in commercial available activated MMP-2
Samples containing 0.13 - 4 % glycerol (0.63 - 20 µg/mL enzyme) was incubated with or
without 0.5 % BSA for 20 h at 37◦C. Samples were denatured by SDS and analyzed by
gelatin zymography. 1 ng enzyme was loaded in each lane.
2.3.12 DQ gelatinase cleavage assay
MMP activity was measured by EnzChek Gelatinase Assay Kit (Molecular Probes Inc., OR).
Enzyme samples containing 0.32 - 10 % glycerol (1.6 - 50 µg/mL enzyme) was incubated
with 12.5 µg/mL dye-quenched (DQ) gelatin in activation buffer [50 mM Tris-HCl (pH 7.6),
1.5 mM NaCl, 0.5 mM CaCl2, and 1 µM ZnCl2] for 2 h at 37
◦C with or without addition of
0.5 % BSA. Fluorescence was measured at 485 nm excitation and 530 nm emission as rec-
ommended by the manufacturer using an Infinite 200 microplate reader (Tecan, Ma¨nnedorf,
Switzerland).
2.3.13 Liposome formation
Stock solutions were prepared by dissolving the lipids in 1:1 tert-butanol/water. The final
concentration of DOTAP was 1 mg/mL and 4 mg/mL for POPC. DOPE-PEG2000 was
prepared in 1:3 tert-butanol/water to a final concentration of 1 mg/mL. For DOTAP, DOPE-
PEG2000, or RJ111 formulations the desired amount of lipid was added on the expense of
POPC material. All formulations contained 0.5 mol% DOPE-Rhodamine B. The appropriate
volumes of lipid material were mixed, frozen in liquid nitrogen and lyophilized overnight to
yield a lipid film with the desired lipid composition. The lipid mixtures were hydrated in 10
46
2.3 Materials and methods
mM HEPES (pH 7.5) and 150 mM NaCl for 1 h, subsequently exposed to 6 freezing-thawing
cycles and extruded by use of an Avanti-mini extruder through a 100 nm polycarbonate filter
(Avanti Polar Lipids, AL) resulting in a 10 mM liposome suspension.
Formulation Composition Molar ratio ζ-potential Size
mol% mV nm
RJ111 1 POPC:DOTAP 90:10 0.0 ± 1.3 130 ± 1
2 POPC:DOTAP:RJ111 80:15:5 -5.0 ± 2.0 112 ± 1
Molar ratio Lipid Oxaliplatin
mol% nM mg/mL
RJ111 4 POPC:DOPE-PEG2000 95:5 75 1.25
and 5 POPC:DOTAP:RJ111 80:15:5 75 0.93
Oxaliplatin 6 POPC:DOTAP:D-RJ111 80:15:5 75 0.48
Table 2.1: Overview of MMP sensitive liposomes. List of liposomes composed of POPC, DOTAP,
DOPE-PEG2000, Lipopeptide with MMP-2 cleavable sequence (RJ111), and Lipopep-
tide with MMP-2 non-cleavable sequence (D-form, D-RJ111). Ratio of each component
in the liposomes is shown.
2.3.14 Liposome size and charge measurement
The mean particle size and charge of the liposomes were measured by dynamic light scatter-
ing (DLS) on a ZetaPALS zeta potential analyzer (Brookhaven Instruments Coorporation,
Holtsville, NY). All liposome formulations (listed in table 2.1) were extruded through a 100
nm polycarbonate membrane.
2.3.15 Flow cytometry (FACS) analysis of adherent cells
Liposome preparations (10 µM) were incubated with active MMP-2 (25 µg/mL) or ther-
molysin (25 µg/mL) in activation buffer [50 mM Tris-HCl (pH 7.6), 1.5 mM NaCl, 0.5 mM
CaCl2, and 1 µM ZnCl2] for 24 h at 37
◦C. They were added to 105 cells in a 24-well plate in
medium with or without FBS. Samples were incubated for 1 h at 37◦C. Cells were washed in
PBS and trypsinized to obtain a single cell suspension. Medium was added and the samples
were centrifuged at 1200 g for 5 min, resuspended in 1 mL FACS buffer (PBS supplemented
with 1 % bovine serum albumin, BSA), and immediately centrifuged at 1200 g for 5 min.
Cells were resuspended in 400 µL FACS buffer and transferred to a 96 well plate with round
bottom (Nunc, Roskilde, DK), before being subjected to flow cytometric analysis, which were
carried out on a BD FACSArray bioanalyzer (Becton Dickinson, Franklin Lakes, NJ, USA).
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The cellular association was determined based on the fluorescence of DOPE-rhodamine B
incorporated into the liposomal membrane. The total amount of liposome associated with
cells was estimated using excitation at 532 nm and emission at 564-606 nm. Data were
analyzed by BD FACSDiva Software v5.0.2.
2.3.16 FASC analysis of cells in human blood
Liposome preparations (10 µL, 10mM) were incubated with active MMP-2 (25 µg/mL) or
thermolysin (25 µg/mL) in activation buffer [50 mM Tris-HCl (pH 7.6), 1.5 mM NaCl, 0.5
mM CaCl2, and 1 µM ZnCl2] for 24 h at 37
◦C. Peripheral blood was obtained from healthy
volunteers in BD Vacutainer containing ethylenediaminetetraacetic acid (EDTA, 366450).
Liposome preparations were added to 200 µL fresh blood in 1.5 mL eppendorf tubes. Samples
were incubated for 1 h at 37◦C with rotation. Red blood cells (RBC) were lysed in 4 mL BD
Pharm lysis buffer in the dark at room temperature (RT) for 15 min in BD serum Vacutainer
(367614), centrifuged at 200 g for 5 min, and resuspended in 1 mL Pharm lysis buffer. After
5 min incubation in the dark at RT, samples were centrifuged at 200 g for 5 min, resuspended
in 1 mL FACS buffer (PBS supplemented with 1 % BSA), and immediately centrifuged at
200 g for 5 min. Cells were resuspended in 400 µL FACS buffer and transferred to a 96 well
plate with round bottom (Nunc, Roskilde, DK), before being subjected to flow cytometric
analysis, which were carried out on a BD FACSArray bioanalyzer as previously described.
Liposome association with monocytes was analyzed based on their location in forward/side
scatter plot.
2.3.17 In situ zymography
Gelatinolytic activity in tissue sections was demonstrated as described by Mook et al. (2003).
7 µm cyrosections were prepared from unfixed frozen tumor tissue. The cryostat sections
were airdried for 10 min. Dye-quenched (DQ) gelatin substrate (Enz-Chek; Molecular Probes,
Eugene, OR) was dissolved in water (1 mg/mL) and subsequent diluted 1:10 in 1% (w/v) low
gelling temperature agarose (Sigma) in PBS. DAPI (1.0 µg/mL) was added to counterstain
nuclei. 40 µL was added to each section and covered with a coverslip. After gelling of the
agar at 4◦C, the slides were incubated for 1 h at RT. The slides were imaged with an Axio
Imager Z1 epi-ourescent microscope (Zeiss, Oberkochen, Germany). FITC was detected with
excitation at 460-500 nm and emission at 512-542 nm. DAPI was detected with excitation
at 340-380 nm and emission over 425 nm.
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2.4 Results
2.4.1 The substrate sequence cleaved by MMP-2 in vitro
To ensure the substrate sequence used in the drug delivery system (Gly-Ile-Pro-Val-Ser-Leu-
Arg-Ser-Gly-Gly) could be cleaved by aMMP-2 it was incubated with pre-activated enzyme
and analyzed by HPLC (Fig. 2.1). In addition to aMMP-2, the activation by aMMP-
9 and thermolysin, an enzyme from Bacillus thermoproteolyticus rokko, was investigated.
Thermolysin should in theory be able to cleavage the sequence (Heinrikson, 1977) and was
evaluated for potential use as a model enzyme for activation. Furthermore, it had potential
for large scale experiments, where the amount of enzyme would be the limiting factor due to
cost. Thermolysin is an extracellular metalloendopeptidase with low substrate specificity and
is, like MMP-2, dependent on zinc and calcium ions as cofactors. The results demonstrated
that the substrate could be cleaved by aMMP-2 (Fig. 2.1). Furthermore, it could be cleaved
by both aMMP-9 and thermolysin (data not shown). All three enzymes will be able to
activate the drug delivery system.
Figure 2.1: Cleavage of substrate sequence was analyzed by HPLC. (A) APMA buffer, (B) peptide
in buffer containing APMA, and (C) peptide and aMMP-2 in APMA buffer. The black
box shows the peptide and the red box shows the cleavage products.
2.4.2 Active MMP-2 expressed by the cancer cell line HT1080 in vitro
Gelatinases are expressed in most human cancers in vivo as well as cancer cell lines cultured
in vitro. We wanted to develop an animal model with high expression of active gelatinases
for evaluation of the activation mechanism in vivo. To find candidates for in vivo models the
presence of different isoforms of gelatinases on the surface of human cancer cell lines and in
CM from the cells was analyzed. Four different human cancer cell lines were selected on basis
of their secretion of gelatinases reported in the literature; HT1080 (fibrosarcoma cell line),
786-0 (renal carcinoma cell line), LOX IMVI (melanoma cell line), and MDA-MB-435 (breast
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carcinoma cell line) (Fig. 2.2A). Cancer cell lines have been reported to up-regulate the
expression of gelatinases in vitro after stimulation with PMA (Williger et al., 1999) or ConA
(Overall & Sodek, 1990). Both compounds enhance the expression of pro-MMP-2 and MT1-
MMP (MMP-14), which subsequently activates pro-MMP-2 (Strongin et al., 1995). Cells
were cultured in serum free medium with PMA or ConA stimulation for 24 h before medium
and cells were collected. Secretion of gelatinases from the four cell lines and subsequent
activation was analyzed by gelatin zymography. Since inactive isoforms are activated as a
result of denaturation and renaturation of the proteins during preparation, all isoforms with
a functional active site can be detected.
The zymogram revealed that HT1080, 786-0, and LOX IMVI all secreted pro-MMP-2
to the medium with or without stimulation. LOX IMVI furthermore secretes pro-MMP-9
(Fig. 2.2B). HT1080 express pro-MMP-2 and active MMP-2 on the cell surface without
stimulation, whereas after stimulation with PMA or ConA active MMP-2 can in addition
be detected in CM from HT1080 cells. PMA stimulation further induces expression of pro-
MMP-9 in HT1080 and 786-0. MDA-MB-435 neither expressed MMP-2 nor MMP-9 and
was included in the study as a negative control cell line for in vivo studies. Murine cells
express gelatinases of 72 and 92 kDa, corresponding to the human MMP-2 and MMP-9,
respectively, and these cannot be distinguished from the enzymes expressed by the human
cancer cells (Lorenzo et al., 1992).
Figure 2.2: Gelatinase expression in vitro. (A) Phase contrast microscopy pictures of the cancer
cell lines: HT0180, 786-0, LOX IMVI, and MDA-MB-435. (B) Zymograms showing
expression of MMP-2 and MMP-9 on the surface of cells and secreted into the con-
ditioned medium (CM). The cells are stimulated with 50 ng/mL PMA or 20 µg/mL
ConA for 24 h.
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2.4.3 Active gelatinases expressed by tumor tissue in vivo
Expression of MMP-2 and MMP-9 in vivo is of great importance, since the drug delivery
system will be activated in tissues expressing active forms of these enzymes. They are known
not to be present in healthy tissues at high concentrations, unless these undergoes remodelling
(Page-McCaw et al., 2007), but expressed in high levels in cancerous tissues (Kessenbrock
et al., 2010). First, the expression of gelatinases in healthy mouse tissues was determined by
gelatin zymography. Tissue was obtained from mouse heart, lung liver, kidney, and spleen.
Equal amounts (wet weight) were homogenized with or without pro-MMP-2, to ensure the
enzymatic activity was not affected by the homogenization procedure. 1 ng pro-MMP-2 was
loaded with the samples as well as in the MMP-2 control. The results revealed that the lung,
kidney, and spleen contained pro-forms of both MMP-2 and MMP-9. Active isoforms of the
gelatinses were not detected in the healthy tissue (Fig. 2.3A).
Next, the 4 selected cancer cell lines were implanted subcutaneously (s.c.) in the back of
nude mice and subsequently analyzed for gelatinase expression by gelatin zymography. The
cells expressed the same gelatinases in vivo as observed in vitro together with the active
isoform of MMP-2 (Fig. 2.3B). HT1080 and LOX IMVI expressed pro-MMP-9 as previously
observed after PMA stimulation in vitro (Fig. 2.2). MDA-MB-435, included as a negative
control cell line, only expressed pro-MMP-2, which may be a result of the microenvironment
in vivo compared to in vitro conditions. These data, along with the analysis of the cell lines
in vitro, demonstrated that HT1080 was the best tumor model to use for in vivo evaluation
of the drug delivery system.
Figure 2.3: Gelatinase expression in healthy and cancerous tissues. (A) Zymograms showing ex-
pression of gelatinases in (A) healthy mouse tissue and (B) tumors made in nude mice
from the human cancer cell lines 786-0, HT1080, LOX IMVI, and MDA-MB-435.
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2.4.4 Requirement for pre-activation of MMP-2 for in vitro cleavage studies
Knowledge about gelatinases expression and activity is essential for in vitro evaluation of
the MMP-2 activated drug delivery system. In vitro, pro-MMP-2 can be activated with 1
mM APMA, a mercury-containing compound that destabilizes the interaction between the
pro-peptide and the zinc-ion in the active site (Visse & Nagase, 2003). A time study was
performed to optimize APMA-activation of pro-MMP-2, where the enzyme was incubated
with 1 mM APMA at 37◦C and samples were taken at the designated time points. The
zymogram revealed that pro-MMP-2 was fully activated after 20 min incubation with APMA
(Fig. 2.4A). MMP-2 undergoes autolytic processing, resulting in inactive isoforms of the
enzyme not visible on the zymogram and therefore decreased activity as a result of incubation
time (Okada et al., 1990).
Figure 2.4: Activation of pro-MMP-2 by APMA. (A) Gelatin zymography. Pro-MMP-2 was acti-
vated with APMA and samples were taken at the designated time points. (B) Phase
contrast microscopy pictures of the cancer cell lines HT0180 and 786-0 after 4 h in-
cubation with 0 - 12.5 µM APMA. (C) Liposome induced cytotoxicity was measured
on HT1080 cells after 4 h incubation with 0 - 12.5 µM APMA and subsequent culture
for 72 h in fresh medium.
However, as a result of the cytotoxic nature of the mercury-containing APMA, this method
of activation may not be used for cell culture experiments (Dean & Overall, 2007). To
address the potential toxicity of APMA, the two cancer cell lines HT1080 and 786-0 were
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incubated with concentrations of APMA ranging from 0 - 12.5 µM for 4 h. The cells change
morphology after treatment with APMA at concentrations above 1 µM (Fig. 2.4B). The cells
were subsequently cultured in fresh medium for 72 h before the viability was investigated by
addition of XTT (Fig. 2.4C). APMA was toxic to the cells at concentration above 0.4 µM.
At 0.8 µM only 80 % of cells were viable compared with the control. As a result, pro-MMP-2
pre-activated with APMA cannot be used for cell culture experiments.
2.4.5 Stability of active MMP-2 prolonged with gelatin and BSA
To be able to evaluate the performance of the liposomal drug delivery system in vitro,
experimental conditions had to be optimized to ensure maximal activity of aMMP-2. The
stability of 0.5 ng/µl aMMP-2, with addition of 250 µg/ml gelatin or 0.5 % BSA, was
determined by gelatin zymography (Fig. 2.5A). Enzyme samples were incubated at 37◦C and
analyzed at time points between 0 and 20 h. The enzyme alone was degraded within 4 h
(Fig. 2.5A, top panel), whereas addition of gelatin (Fig. 2.5A, middle panel) or BSA (Fig.
2.5A, bottom panel) decreased enzyme autolysis, which resulted in detection of aMMP-2
after 6 h incubation at 37◦C. BSA stabilized the aMMP-2 to such an extent that presence
of active enzyme after 20 h was observed.
This experiment was conducted with low enzyme concentration, which may not be suf-
ficient for activation of the liposomes in vitro. For experiments with high enzyme concen-
tration, however, another challenge occurs. Commercially available recombinant enzyme
contains glycerol as a stabilizing agent, which has an inhibitory effect on enzyme activity
(Bradbury & Jakoby, 1972). The ratio between enzyme and glycerol is of great importance
and as a result of investigating the effect of glycerol concentration, the enzyme concentration
had to vary in the samples. This is, however, the best way to determine the optimal incu-
bation conditions for maximal activity, as the liposomes will be pre-activated with enzyme
in a small volume before being analyzed for cell association. To find the optimal enzyme
concentration a dilution series with 0.32 - 10 % glycerol was made and incubated with DQ
gelatin for 2 h, with or without addition of 0.5 % BSA, to investigate the enhanced stabilizing
effect, the fluorescence was measured. It was found that enzyme in 5 % glycerol has a higher
activity than twice the amount in 10 % glycerol (Fig. 2.5B). Since addition of BSA may
interfere with cell-liposome association and makes MALDI-TOF MS analysis of the samples
difficult, a concentration of 5 % glycerol was determined to be optimal for in vitro cleavage
studies.
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Figure 2.5: Stabilization of aMMP-2 with gelatin or BSA. (A) Gelatin zymogram was performed
after 0 - 20 h aMMP-2 (0.5 ng/µL) incubation with 0.25 mg/mL gelatine (middle)
or 0.5% BSA (bottom). (B) Activity of samples with the designated concentrations
of glycerol was measured by cleavage of DQ fluorescent gelatin substrate after 2 h
incubation at 37◦C.
2.4.6 Cationic peptide facilitated association between liposomes and cells
It is a widely recognized phenomenon that liposome formulations with a positive charge
interact with cells, due to the negatively charged outer cell membrane (Hock & Sto¨hr, 1977).
However, these cationic systems have been reported to be cytotoxic (Lv et al., 2006). In
the original design of the drug delivery system, the peptide contained positively (arginine,
R) and negatively (aspartate, D) charged amino acids on each side of the MMP-2 cleavable
sequence (Rn GIPVS-LRSGGDn−1) . The negative amino acids were removed after cleavage
of the substrate sequence, whereas the positive amino acids remained, resulting in a positively
charged liposome.
We wanted to determine the amount of positive charge needed for enhancement of
cell-liposome interaction as well as potential cytotoxicity of the formulations (Fig. 2.6).
Lipopeptides resembling the lipopeptide after cleavage containing 3 and 5 arginines together
with a lipopeptide with 8 arginines were synthesized (stearic acid-RRRGIPVS, stearic acid-
RRRRRGIPVS, and stearic acid-RRRRRRRR). Rhodamine B labeled liposome formulations
with 5 % of the different lipopeptides were prepared and added to adherent cell cultures for
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1 h in serum free medium. The cells were analyzed by FACS, where the results revealed
that addition of positively charged lipopeptides increased the interaction between liposomes
and cells (Fig. 2.6A). Furthermore, it was demonstrated that liposomes formulated with
lipopeptides containing more than 3 arginines were toxic to the cells (Fig. 2.6B).
Figure 2.6: Optimization of the cationic charge. (A) FACS analysis of cell associated liposomes
after 2 h incubation with liposomes containing lipopeptide with 3, 5, or 8 arginines.
Liposome without lipopeptide is used as control. Mean ± SD. (B) Phase contrast
microscopy pictures of the cell line 786-0 after incubation with liposomes for 3 h.
The design, however, was changed after these initial studies due to potential folding of
the bipolar lipopeptide-PEG conjugate, risking a decreased enzyme activation. Instead of
the original design with positively charged amino acids at one end of the substrate sequence
and negatively charged amino acids at the other end, a PEG-conjugated lipopeptide (stearic
acid-GIPVS-LRSGGDD-PEG, RJ111), containing 2 negatively charged amino acids on the
PEG-side of the MMP-cleavable sequence, was synthesized. 5 % RJ111 was formulated with
15 % DOTAP, each containing one positive charge, resulting in a neutral liposome. This new
design further enabled optimization of cellular association by change of positive or negative
charge independent of each other.
2.4.7 Activation of liposomes resulted in increased cell association in vitro
The ability of the enzyme to cleavage the substrate sequence, when RJ111 was formulated in
a liposome, was evaluated. To investigate the activation mechanism in vitro, aMMP-2 and
thermolysin was pre-incubated with liposome containing the RJ111 conjugate for 24 h, before
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being added to adherent cells in serum free medium. Liposomes were subsequently incubated
with cells for 1 h before subjected to FACS analysis. Significantly increased cell-association
of the liposome formulation was observed after thermolysin activation, indicating enhanced
cell interaction as a result of shedding the coating PEG layer and subsequent shift in surface
charge. Enhanced association was not observed after activation with aMMP-2. Addition
of serum to the culture medium during the incubation time with liposomes decreased the
association of liposomes with the cells (Fig. 2.7A).
Figure 2.7: Interaction of cleavable liposomes with cells. (A) FACS analysis of HT1080 cells after
1 h incubation with liposomes containing RJ111 and 15 % DOTAP in medium with or
without FBS. Liposomes were pre-treated with 25 µg/mL aMMP-2 or thermolysin for
24 h. (B) FACS analysis of monocytes from human whole blood after 1 h incubation
with liposomes containing RJ111 and 10, 15, or 25 % DOTAP. Liposomes were pre-
treated with 25 µg/mL aMMP-2 or thermolysin for 24 h. Data are expressed as mean
florescent intensities of rhodamine B shown as mean ± SD (**** P<0.0001, ns = not
significant)
2.4.8 Cleavable pegylated liposomes were not recognized by human blood monocytes
We developed an assay for detection of monocyte associated liposomes, since these cells are
part of the MPS that recognize and phagocyte administered liposomes. The association of
three formulations, containing 10, 15, and 25 % positively charged DOTAP, was investigated
(Fig. 2.7B). The liposomes containing RJ111 with 10 and 15 % DOTAP were not associated
with monocytes without prior enzymatic activation with thermolysin. Addition of 25 %
DOTAP resulted in cell association of the liposomes as a result of the positive charge.
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2.4.9 Gelatinase active in murine tumor models
The expression and activity in experimental models to be used for proof of concept of the
drug delivery system was investigated. The different isoforms of gelatinases in tumor tissue
from the HT1080 cell line were analysed by zymography, revealing presence of active MMP-2
(Fig. 2.8A). Furthermore, to determine where the activity was localized, in situ zymography
was performed on the tumor tissue. In situ zymography is a method for detecting activity
on a cryosection of unfixed frozen tissue. Fluorescence occurs when active gelatinases are
present in the tissue. There was activity in the HT1080 tumor, both at the core of the tumor
and at the edge of the tumor sample (Fig. 2.8B). These results further enable the use of
HT1080 tumor model for demonstration of enzymatic activation of liposomes in vivo.
Figure 2.8: Gelatinase activity in tissue from HT1080 tumor model. (A) Zymogram showing
expression of gelatinases in the tumor tissue. (B) Representative pictures of in situ
zymography performed on cyrosections prepared from unfixed frozen HT1080 tumor
tissue. DAPI stains the nucleus and DQ gelatin FITC shows gelatinase activity in the
tissue.
2.4.10 Gelatinase activity in patient-derived colon cancer models
Liposome encapsulated oxaliplatin, a platinum-based drug used in the treatment of colon
cancers, was used as a model drug for evaluation the performance of the drug delivery system
in vivo. The HT1080 tumor model was not sensitive to free oxaliplatin (Iduna Fichtner,
personal communication). To ensure having an oxaliplatin sensitive model for in vivo testing
we analyzed several patient-derived xenograft models of colon cancer. All models expressed
active MMP-2 (Fig. 2.9A). Furthermore, in situ zymography demonstrated activity in all
analyzed samples (Fig. 2.9B).
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Figure 2.9: Gelatinase activity in xenograf colon cancer tumor tissue. (A) Zymogram showing
expression of gelatinases in the tumor tissue. (B) Representative pictures of in situ
zymography performed on cyrosections prepared from unfixed frozen xenograf colon
cancer tumor tissue. DAPI stains the nucleus and DQ gelatin FITC shows gelatinase
activity in the tissue.
2.4.11 Gelatinase activity in clinical samples from cancer patients
The expression and activity of gelatinases in human cancer tissues was investigated to validate
the use of MMP-2 as a enzymatic trigger of drug release in cancerous tissues. The activity
in the human tumor samples from 4 breast cancers, 3 colon cancers, and 1 ovary cancer
was analyzed by gelatin zymography and in situ zymography to investigate the presence of
different isoforms at the edge of the tumor samples and in the core, as well as the activity
of the gelatinases (Fig. 2.10). Breast, ovary, and colon cancer all expressed active forms of
MMP-2 (Fig. 2.10A). This was confirmed by in situ zymography that revealed high gelatinase
activity in all tumors (Fig. 2.10B).
58
2.4 Results
Figure 2.10: Gelatinase activity in clinical samples. (A) Gelatin zymography showing expression of
gelatinases in breast, ovary, and colon cancer. (B) Representative pictures of in situ
zymography performed on cyrosections prepared from unfixed frozen clinical cancer
samples; breast cancer (top panel), ovary cancer (middle panel), and colon cancer
(bottom panel).
2.4.12 Greater effect in vitro of liposome encapsulated oxaliplatin than free oxaliplatin
Oxaliplatin was encapsulated into the RJ111 liposomes as a model system for in vitro and in
vivo evaluation of the drug delivery system. The cytotoxic effect of liposome encapsulated
oxaliplatin vs. free oxaliplatin was tested in vitro on the HT1080 cell line. Liposomes con-
taining 5 % RJ111, 15 % DOTAP, and 0.93 mg/mL oxaliplatin were formulated. Liposomes
containing oxaliplatin were pre-incubated with thermolysin for 1 h and subsequently added
to HT1080 cell cultures at concentrations ranging from 1.6 µM to 25 µM oxaliplatin (Fig.
2.11A). Free oxaliplatin and empty liposomes were used as controls at the same concentra-
tion as the liposome encapsulated oxaliplatin. Cells were washed and cultured for in fresh
medium before viability of treated cells was analyzed.
Oxaliplatin-induced cytotoxicity was measured by incubation of the HT1080 cells with
XTT. Liposome encapsulated oxaliplatin induced cytotoxicity at low concentrations, whereas
the free drug were significantly less cytotoxic. At 6.3 µM 85 % of cells were alive compared
to the control, whereas only 20 % of the cells treated with oxaliplatin encapsulated liposomes
were alive. However, no significant difference was observed between pre-activated liposomes
and PEGylated liposomes.
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Figure 2.11: Toxicity of oxaliplatin encapsulated liposomes. (A) Toxicity of different concentra-
tions of free oxaliplatin and oxaliplatin encapsulated in liposomes containing RJ111
incubated with HT1080 cells for 5 h and subsequent culture for 72 h before analysed
by XTT. (B) Toxicity of different concentrations of free oxaliplatin and oxaliplatin
encapsulated in liposomes containing RJ111, D-RJ111, or PEG2000 incubated with
HT1080 cells for 90 min and subsequent culture for 72 h before analysed by XTT.
(C) Same experiment as in (B) except the liposomes are pre-treated with 50 µg/mL
thermolysin for 1 h.
As previously described, HT1080 cells expressed active MMP-2 on the surface. It was
possible that the liposomes were activated as a result of active gelatinases in the cell cultures.
To investigate this, a D-analogue of the lipo-peptide (D-RJ111) was synthesized. This
peptide was conjugated to PEG and formulated in the same way as RJ111 as a non-cleveable
control liposome containing 48 mg/ml oxaliplatin. Furthermore, two additional formulations
were included; a control RJ111-liposome without oxaliplatin and a liposome with PEG coating
and oxaliplatin (PEG2000), but without cleavable sequence or any additional charge, resulting
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in a negatively charged liposome. For increased sensitivity, cells were incubated for 90 minutes
with liposomes (Fig. 2.11B-C). After 90 minutes free oxaliplatin was only significantly toxic
to the cells in vitro at 50 µM compared with the untreated control. RJ111 was toxic with
or without addition of thermolysin, whereas D-RJ111 was toxic without thermolysin (Fig.
2.11B). Addition of thermolysin decreased the association of D-RJ111 containing liposomes
with cells (Fig. 2.11C), indicating the absorption of liposomes is decreased as a result of
adsorption of enzyme to the surface of the liposomes.
2.5 Discussion
The use of chemotherapeutics in the clinic is far from ideal. Side effects associated with drug
distribution to healthy tissues limit the maximal doses that can be administered, leading to
poor drug bioavailability in cancerous tissues. As a result, oncologists have to walk a fine
line between therapeutic efficacy of the treatment and damage of vital organs. Systemic
distribution of chemotherapeutics is problematic due to the relatively unspecific action of the
drugs, which are designed to destroy rapidly dividing cells and therefore affect most tumor
cells, but also damage organs in the body with high cell turnover (Kuijpers et al., 2010).
The ideal chemotherapeutic agent is given systemically after which it localizes in tumor tissue
and, not until then, have a toxic effect on the cells, resulting in high bioavailability of the
drug and few side effects due to action on healthy tissues.
Most of this can be achieved by drug encapsulation in pegylated liposomes that localizes in
cancerous tissue as a result of the EPR effect and show decreased toxicity to healthy tissue;
however, enhanced bioavailability is challenging to achieve. As a result, controlled release of
drugs has gained increased attention the last decade and several strategies for active release
of encapsulated drug in the extracellular space have been developed (Jensen et al., 2004;
Sarkar et al., 2005; Hatakeyama et al., 2007a). We here presented a rationally designed novel
pegylated drug delivery system that utilize the enhanced MMP-2 activity in cancerous tissue
for enzymatic removal of a negatively charged PEG coating, resulting in cationic liposomes.
To our knowledge, this study is the first report of a MMP-2 sensitive drug delivery system
that after shedding the PEG coating changes charge, resulting in cationic liposomes with
enhanced cell association.
In vitro cleavage studies were conducted with recombinant enzymes to ensure activity was
a result of one specific enzyme and not other enzymes from the cells. Enzymatic activation
of the liposomes by MMP-2 was essential for the design and therefore, it was confirmed
by HPLC that MMP-2 treatment of the substrate sequence resulted in hydrolysis of the
peptide. Furthermore, it was demonstrated that the sequence could be hydrolyzed by active
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MMP-9, due to their overlapping substrate specificities (Xu et al., 2005). MMP-9 is also
overexpressed in tumors, hence the ability of this enzyme to activate the liposomes enhances
the activation rate in cancerous tissue. Cleavage of the substrate by another endopeptidase,
thermolysin, was also evaluated (Heinrikson, 1977). It is less specific in its substrate affinity
and is more stable than MMP-2, which is degraded rapidly due to autolysis (Okada et al.,
1990). The activity of thermolysin is substantial longer and it might be useful as a model
enzyme for demonstrating the activation mechanism of the system in vitro.
After these initial studies, however, we found that APMA, commonly used for pro-MMP-2
activation in vitro, was cytotoxic and could not be used in cell studies of liposomal association
(Dean & Overall, 2007). A commercially available pre-activated MMP-2 was used as an
alternative and experimental conditions were optimized to achieve maximal activity with the
highest possible enzyme concentration. The enzyme contained 20 % glycerol as a stabilizing
agent, which has an inhibitory effect on MMP-2 activity (Bradbury & Jakoby, 1972). It was
determined that an enzyme concentration of 25 µg/mL (0.4 µM) containing 5 % glycerol
was optimal for in vitro cleavage studies. This concentration is lower than the physiological
levels in cancerous tissue, as Hatakeyama et al. (2007a) have estimated the extracellular
MMP-2 concentration in tumor tissue to be 1 mM.
The design of the delivery system presented here exploits the enhanced ability of cationic
liposomes to interact and, depending on the physiochemical properties of the formulation,
fuse with cell membranes (Hock & Sto¨hr, 1977; Noguchi et al., 1998). The amount of cationic
charge was evaluated by formulating liposomes with lipopeptides containing different amounts
of positively charged arginines. We determined that 5 % peptide containing 3 arginines,
each having one positive charge, were optimal for enhanced cell-liposome interaction while
still avoiding cytotoxicity of the liposomes. As previously reported, significantly higher cell
association was observed with the positively charged liposomes compared to neutral liposomes
(Jung et al., 2009).
In our study, enzymatic activation of the neutrally charged liposomes containing RJ111
resulted in significantly higher cell-association compared to that of neutrally charged non-
pegylated liposomes, demonstrating the ability of liposomes to change charge after activation.
The liposomes could be activated by thermolysin, but we did not succeed in activating
the liposomes with aMMP-2 in vitro. This may be a result of rapid autolysis of MMP-2
compared with thermolysin (Okada et al., 1990). Both Hatakeyama et al. (2007a) and Terada
et al. (2006) succeed in activation of their liposomal delivery systems in vitro. However,
Hatakeyama et al. (2007a) reported that their system was activated with CM from HT1080
cells and that the sequence was designed to be cleaved by other MMPs than MMP-2. Terada
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et al. (2006) activated their liposomes with 5 µg enzyme in 1 mL, which is more than we used
in our studies, which was 25 µg/mL in 20µL (0.5 µg). In vivo the sustained secretion and
activation of enzymes from the cells at the site of the tumor, resulting in high concentration
of active enzyme in the extracellular space, will potentially be sufficient for activation of the
liposomes. The fact that the drug delivery system was activated by thermolysin, resulting
in significantly enhanced cell association, demonstrated the efficiency of the design, where
enzymatic removal of the negatively charged PEG coating resulted in change of liposomal
charge. Furthermore, our results indicate that the liposomes were able to avoid uptake by the
MPS, in contrast to positively charged liposomes without PEG. These results will, however,
have to be confirmed on more donors.
We tested the cytoxicity of the system in vitro by encapsulating oxaliplatin in the liposomes
and observed significantly higher effect of liposome encapsulated oxaliplatin compared to the
free drug. However, we did not observe differences between liposomes pre-activated with
thermolysin and liposomes with intact PEG coating. In addition, the liposomes with the
non-cleavable D-analog were cytotoxic in vitro. This was a result of the RJ111 conjugate,
since oxaliplatin encapsulated in pegylatede liposomes were not toxic to the cells in our
studies. This formulation was actually comparable to the cisplatin containing formulation
SPI-077, which did not did not show enhanced therapeutic efficacy (Seetharamu et al., 2010).
Addition of 50 µg/mL thermolysin in our study decreased the association of liposomes with
cells, except from the formulation containing the cleavable RJ111, which may be a result
of adsorption of proteins contributing to additional shielding of the cationic charge in vitro
(Johnstone et al., 2001). Jung et al. (2009) reported that their cationic liposomal system
complexed with PEG demonstrated cytotoxicity in vitro comparable to cationic liposomes,
but they did not observe the enhanced efficacy in vivo. Thus, in vivo studies of the present
system may have different outcome.
We have demonstrated in vitro that MMP-2 can cleave the substrate sequence and that
liposome association with cells was enhanced after enzymatic activation. Due to the diffi-
culties with MMP-2 autolysis, the only way to demonstrate enhanced efficacy as a result of
the activation mechanism may be by conducting an in vivo study. To find a gelatinase ex-
pressing animal model several human cancer cell lines were analyzed, and the results revealed
that the HT1080 cell line expressed active MMP-2 in vitro and in vivo. The MDA-MB-435
tumor model that was included as a negative control as the cells in vitro did not express
gelatinases only expressed pro-MMP-2, which may be a result of stimulation by the microen-
vironment in vivo or enzymes secreted from mouse stroma cells infiltrating the tumor. The
fact that this model did not express active MMP-2 in vivo, confirm that the active MMP-2
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in the HT1080 tumor model are secreted from the implanted cancer cells. In addition, we
evaluated gelatinase activity and expression in several xenograft colon cancer models as well
as in clinical samples from three different types of human tumors; colon, breast, and ovary
cancer, all determined to have active isoforms of galatinases and high gelatinase activity.
Furthermore, we found that the expression of active gelatinases in healthy tissue was low.
Pro-forms were detected in kidney, lung, and spleen, probably secreted from immune cells in
the tissues (Opdenakker et al., 2001), but active isoforms of the enzymes were not detected
in the investigated tissues. Together, these data validate the use of MMP-2 as a specific
trigger of drug release in cancerous tissue.
The research in cancer treatment with liposomal formulations has come far, since it was
discovered that liposomal circulation time could be prolonged with a PEG coating. For a drug
delivery strategy to reach the clinic, release of the load at the right time in the right tissue
is crucial. Doxil is a great example of liposomal drug encapsulation, resulting in enhanced
tumor-accumulation and decreased toxicity of the encapsulated drug (Gabizon, 2001a). Doxil,
however, rely on passive diffusion of the encapsulated DOX and as a result, the strategy can
only be used for delivery of actively loaded amphiphilic drugs (Veldman et al., 2004). The
enhanced efficacy and decreased side effects may also be achieved by liposomal encapsulation
of other chemotherapeutics currently used in the clinic, which cause severe side effects. An
example is oxaliplatin, used in the treatment of colon cancer, which has low bioavailability
due to partitioning into erythrocytes (Pendyala & Creaven, 1993). This obstacle have been
demonstrated to be overcome by encapsulating oxaliplatin in PEG-coated liposomes (Suzuki
et al., 2008; Lila et al., 2009), however, passively loaded oxaliplatin will most likely not be
delivered unless the system has an active trigger mechanism as SPI-077 were not able to
enhance the therapeutic efficacy of the passively loaded cisplatin.
In the drug delivery system presented here we use MMP-2 as an active trigger of drug
release, resulting in removal of the negatively charged peptide-PEG conjugate and thereby
utilize the ability of cationic liposomes to interact with cell membranes. This enhances
delivery of drug specifically into tumor cells once liposomes have accumulated in tumor tissue
due to the EPR effect. The delivery system can be used for delivery of both hydrophilic and
hydrophobic drugs, as long as they execute their actions within the tumor cells, to gelatinase
expressing tumors. Encapsulation of drugs in the system presented here would increase tumor
specific delivery as well as decrease toxicity of the drug, resulting in an improvement of the
therapeutic index as well as life quality of cancer patients.
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3.1 Abstract
Monocytes are known to play an important role in inflammatory diseases, which are commonly
treated with steroids, through their secretion of proinflammatory cytokines. The use of
steroids has, however, limitations due to side effects resulting from drug distribution into
healthy tissues, an event that can be circumvented by the use of specific drug delivery
systems targeting the inflammatory cells, thereby reducing the systemic exposure to the
drug. Here we report the development of a novel drug delivery system that specific target
CD14+ monocytes in human blood. It was found that liposome formulations with a positive
charge between 7.5 - 10 % was optimal for targeting specific to monocytes and it was
observed that this association rapidly occurred in freshly drawn blood. The data revealed
that the use of newly drawn blood was important for mimicking in vivo conditions as close
as possible, since the ability of monocytes to phagocytose liposomes declined relatively fast.
Furthermore, it was demonstrated that these formulations were not toxic to cells in vitro.
Specific targeting to monocytes with the formulation described here, will potentially enhance
therapeutic efficacy of anti-inflammatory drugs while decrease side effects.
3.2 Introduction
Monocytes and neutrophils are the first immune cells to recognize pathogens once invading
the blood stream. Monocytes are recruited to sites of inflammation where they play a major
role in disease progression through secretion of proinflammatory cytokines, such as TNF-α,
IL-1β, and IL-6, and resolution due to phagocytosis of neutrophils in the inflamed tissue
(Serhan & Savill, 2005; Cros et al., 2010; Liddiard et al., 2011).
Sustained release of these cytokines can result in chronic inflammation, and furthermore,
high systemic doses of proinflammatory cytokines can result in sepsis with severe tissue
damage, organ failure, and death (Serhan & Savill, 2005; von Knethen et al., 2005). Thus,
monocytes and their derivatives have been reported to play a central role in development and
progression of inflammatory diseases, such as rheumatoid arthritis (Schmutz et al., 2010),
atherosclerosis (Woollard & Geissmann, 2010), and sepsis (Spittler et al., 2000), due to their
ability to produce large amounts of proinflammatory cytokines.
Inflammation is often treated with potent immunosuppressants, such as steroids, or by
neutralization of inflammatory cytokines with e.g. anti-TNF-α treatment (Thalayasingam &
Isaacs, 2011). However, systemically administered steroids have adverse side effects due to
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lack of specificity, and may lead to development of Cushing’s syndrome (Javaid & Quigg,
2005; Peppa et al., 2011). The distribution of drugs into healthy tissues and rapid excretion
can be circumvented by use of specific drug delivery systems targeting the inflammatory cells
(Allen, 1994; Torchilin, 2005). Thus, development of methods that enables targeted delivery
of therapeutics to monocytes is of great importance in order to improve disease specific
activity and reduce side effects (Ziegler-Heitbrock, 2007; Kelly et al., 2011).
Systemically administered nanotherapeutics, such as liposomes, has proved to enhance
bioavailability of immunosuppressive drugs and decrease side effects in animal models (An-
derson et al., 2010; Chono et al., 2005). Pegylated liposomes can passively accumulate in
inflamed tissue with leaky vasculature after prolonged circulation or non-pegylatede liposomes
can be designed to actively target specific cell types (Andresen et al., 2005). Monocytes,
which are a part of the MPS, play an important role in elimination of pathogens and apop-
totic host cells by phagocytosis (Serbina et al., 2008; Auffray et al., 2009; Mikolajczyk et al.,
2009). Liposomes are also recognized and phagocytosed by the different cells of the MPS
dependent on the physiochemical properties of the liposome formulations. This ability has
been utilized in attempts to develop strategies for targeted delivery of drugs to inflammatory
cells (Vonarbourg et al., 2006; Karathanasis et al., 2009; Leuschner et al., 2011).
Liposome formulations with anti-inflammatory drugs are currently being investigated for
potential clinical use. Liposome encapsulated dexamethasone phosphate (DxM-P) enhances
as well as prolongs the anti-inflammatory effect compared with the free drug in atherosclerotic
mice (Chono et al., 2005) and in a rat model of rheumatoid arthritis (Anderson et al., 2010).
Furthermore, liposome encapsulated chemokine receptor CCR2 siRNA showed reduced mono-
cyte migration in mice and improved the inflammatory conditions in atherosclerotic mice
(Leuschner et al., 2011).
In addition, several liposomal formulations, executing their actions through cells of the
MPS, are already approved for use in the clinic, including the broad-spectrum antifungal
drug AmBisome R© (Walsh et al., 1998) and the immunomodulator Mepact R© containing the
NOD2 receptor agonist mifamurtide (MTP-PE), (Kager et al., 2010). These treatments
could potentially be further improved by specifically targeting the immune cells essential for
the therapeutic effect, believed to be monocytes, thereby potentially reducing the dose as
well as the side effects, resulting in an increased therapeutic window (Hofkens et al., 2011).
We here report a novel liposomal formulation that specifically target CD14+ monocytes
in peripheral blood ex vivo. We show that liposomes with a positive charge were able to
specifically target monocytes when incubated in fresh human whole blood.
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3.3 Materials and methods
3.3.1 Materials
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-dioleoyl-3-trimethylammonium-
propane (DOTAP), 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1’-rac-glycerol) (POPG) and
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]
(DOPE-PEG2000) were obtained from Avanti Polar Lipids (Alabaster, AL, USA) and used
without further purification. Bovine serum albumin (BSA) was obtained from Biofac A/S
(Kastrup, DK). Cell culture reagents were purchased from BioWittaker (Lonza, Verviers, Bel-
gium). Primary pre-conjugated antibodies for flow cytometric analysis [mouse anti-human
CD3 (557851), mouse anti-human CD14 (557742), mouse anti-human CD15 (551376),
mouse anti-human CD19 (557791), mouse anti-human CD56 (555518); isotypes CD3 (557872),
CD14 (557907), CD15 (555585), CD19 (557873), CD56 (555751)], Annexin V (559934), and
all other reagents, unless otherwise specified, were purchased from BD biosciences (Becton
Dickinson, Franklin Lakes, NJ, USA).
3.3.2 Liposome formation
Stock solutions were prepared by dissolving the lipids in 1:1 tert-butanol/water. The final
concentration of DOTAP and POPG was 1 mg/mL and 4mg/mL for POPC. DOPE-PEG2000
was prepared in 1:3 tert-butanol/water to a final concentration of 1 mg/mL. In formulations
containing DOTAP, POPG, or DOPE-PEG2000 the desired amount of lipid was added on the
expense of POPC material. All formulations contained 0.5 mol% DOPE-Rhodamine B. The
appropriate volumes of lipid material were mixed, frozen in liquid nitrogen and lyophilized
overnight to yield a lipid film with the desired lipid composition. The lipid mixtures were
hydrated in 10 mM HEPES (pH 7.5) and 150 mM NaCl for 1 h, subsequently exposed to 6
freezing-thawing cycles and extruded by use of an Avanti-mini extruder through a 100 nm
polycarbonate filter (Avanti Polar Lipids, AL) resulting in a 10 mM liposome suspension.
The mean particle size and charge of the liposomes were measured by dynamic light scatter-
ing (DLS) on a ZetaPALS zeta potential analyzer (Brookhaven Instruments Coorporation,
Holtsville, NY).
3.3.3 Flow cytometry
Peripheral blood was obtained from healthy volunteers in BD Vacutainer containing EDTA
(366450). Liposome preparations (2 - 20 µL) were added to 200 µL fresh blood in 1.5 mL
eppendorf tubes. Samples were incubated for up to 1 h at 37◦C with rotation. RBC were
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lysed in 4 mL BD Pharm lysis buffer in the dark at room temperature (RT) for 15 min in BD
serum Vacutainer (367614), centrifuged at 200 g for 5 min, and resuspended in 1 mL Pharm
lysis buffer. After 5 min incubation in the dark at RT, samples were centrifuged at 200 g for
5 min, resuspended in 1 mL FACS buffer (PBS supplemented with 1 % BSA), immediately
centrifuged at 200 g for 5 min, resuspended in 400 µL FACS buffer and transferred to a
96 well plate with round bottom (Nunc, Roskilde, DK). Unspecific binding were blocked by
human IgG for 10 min on ice before the cells were incubated in 100 µL FACS buffer with
primary pre-conjugated antibody or isotype control for 1 h on ice, and centrifuged at 500 g
for 5 min at 4◦C. Cells were washed twice in 200 µL FACS buffer. Cells were resuspended in
150 µL FACS buffer, before being subjected to flow cytometric analysis, which were carried
out on a BD FACSArray bioanalyzer. The total amount of liposome associated with cells
was determined based on the fluorescence of DOPE-rhodamine B using excitation at 532
nm and emission at 564-606 nm. Liposomal association with five different cell populations
was analyzed based on the following markers: CD14 (monocytic marker), CD15 (neutrophil
granulocyt marker), CD3 (T-lymphocytic marker), CD19 (B-lymphocytic marker), and CD56
(natural killer cell marker). Data were analyzed by BD FACSDiva Software v5.0.2. Unstained
cells were used as negative control, and cells with fluorescence higher than the control cells
were considered positive.
3.3.4 Apoptosis of THP-1 cells
Liposome preparations were added to 200 µL cell suspension (106 cells/mL) in 1.5 mL
eppendorf tubes. The cells were incubated with different concentrations (0, 10, 100, 500,
and 1000 µM) of liposomes for 1 h before the cells were washed twice with fresh media.
Cells were incubated for 24 h at 37◦C in a humidified atmosphere in the presence of 5 %
CO2 in 96 well plates. 10
−6 M (0.26 g/µL) staurosporine was added to one well with cells
and used as positive control for apoptosis. Cells were harvested and washed twice with ice
cold PBS and re-suspended in binding buffer at a concentration of 106 cells/mL. A total of
100 µL of cell suspension was added 1 µL of Annexin V, mixed gently and incubated at RT
for 15 min in dark and analyzed immediately by FACS.
3.3.5 Cell proliferation assay
Cell viability was assessed based on the ability of the cells to convert XTT (Sigma, St. Louis,
USA), into a water-soluble formazan product. Liposome preparations (10 µL) were added to
200 µL cell suspension (106 cells/mL) in 1.5 mL eppendorf tubes. Samples were incubated
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for 1 h at 37◦C with rotation. 105 cells were seeded/well in 100 µL culture medium on a
96-well microtitre plate and incubated for 24 h at 37◦C. XTT labelling mixture (20 µL) was
added and cells were further incubated for 4 h. The absorbance of the samples was measured
at 450 nm subtracted the absorbance at 690 nm as recommended by the manufacturer using
an Infinite 200 microplate reader (Tecan, Ma¨nnedorf, Switzerland).
3.3.6 Statistics
At least 3 independent experiments (on different donors) were conducted for each condition.
Data are represented as percentage of positive cells based on the fluorescence of DOPE-
rhodamine B. The gate showing the percentage of positive cells were set based on the control
cells without addition of liposome and the same gate was used for all cell populations. One
way ANOVA was used to analyze uptake in cells within each condition. Two tailed T-test was
used to analyze uptake in the same cell type when two different conditions were compared.
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3.4 Results
3.4.1 Positively charged liposomes associated with monocytes in whole blood assays
The MPS system is known to be a major clearance system for dead host cells and cellu-
lar debris as well as foreign particles, such as pathogens and nanoparticles. In particular,
liposomes without a PEG coating are known to be cleared by the MPS system (Gabizon
et al., 1991), but how liposomes interact with blood cells in fresh human blood has not been
investigated in detail (Karathanasis et al., 2009; Constantinescu et al., 2003; Kuhn et al.,
1983). We wanted to investigate the interactions of liposomes with different populations of
leukocytes in fresh human blood, dependent on liposome surface charge and PEG coating.
Anionic, neutral, and positively charged liposomes were prepared and analyzed for surface
charge (zeta-potential) and size (Table 3.1 and Fig. 3.1). The neutral phospholipid POPC
was formulated with the negatively charged phospholipid POPG, or the positively charged
phospholipid DOTAP either with or without the PEG polymer coated and negatively charged
phospholipid DOPE-PEG2000.
Formulation Composition Molar ratio ζ-potential
mol% mV
Anoinic 1 POPC:POPG 90:10 -13.1 ± 1.5
2 POPC:POPG:DOPE-PEG2000 90:5:5 -6.0 ± 1.2
Neutral 3 POPC 100 0.0 ± 1.3
4 POPC:DOTAP:DOPE-PEG2000 90:5:5 -0.5 ± 1.4
Cationic 5 POPC:DOTAP:DOPE-PEG2000 80:15:5 11.3 ± 1.2
6 POPC:DOTAP 95:5 22.9 ± 1.3
7 POPC:DOTAP 92.5:7.5 31.2 ± 1.4
8 POPC:DOTAP 90:10 37.7 ± 1.6
9 POPC:DOTAP 87.5:12.5 40.9 ± 1.2
10 POPC:DOTAP 85:15 43.2 ± 1.0
11 POPC:DOTAP 80:20 48.8 ± 1.2
12 POPC:DOTAP 50:50 52.2 ± 2.0
Table 3.1: Overview of liposomes. List of liposomes composed of 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphocholine (POPC), palmitoyl-oleoyl-phosphoglycerol (POPG), 1,2-
dioleoyl-3-trimethylammonium-propane (DOTAP), and 1,2- dioleoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DOPE-PEG2000). The
ratio of each component in the liposomes is shown
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Formulation with 10 % POPC caused a negative liposome surface charge at -13 mV,
whereas formulation with 10 % DOTAP showed a positive charge at 38 mV. For all formu-
lations, the addition of 5 % DOPE-PEG2000 caused decrease in either positive or negative
charge due to a shielding effect of PEG (Dandamudi & Campbell, 2007).
Figure 3.1: Overview of liposome surface charge and size. (A) Liposome surface charge expressed
in mV. (B) Liposome size measured in nanometer (nm). Liposome compositions refer
to the numbers from Table 3.1.
We investigated the interaction of liposome formulations with cells in freshly drawn human
peripheral blood (formulation 1 - 5 + 8 in Table 3.1). Liposomes were added to the blood
and incubated for 1 h at 37◦C under gentle rotation in order to mimic the blood flow in
vivo. Leukocytes were analysed by FACS using cell specific antibodies and the amount
of rhodamine B were measured as expression of liposome associated leukocytes. Anionic
and neutral liposomes were not associated significantly with monocytes (CD14), neutrophil
granulocytes (CD15), T-lymphocytes (CD3), B-lymphocytes (CD19), or natural killer cells
(CD56), compared to the untreated control cells. Three different types of granulocytes
exist; neutrophils, eosinophils, and basophils. Neutrophils express CD15 on their surface,
which is associated with phagocytosis (Kucukkaya et al., 2001). The CD15+ neutrophil
granulocytes, constituting approximately 70 % of all leucocytes in peripheral human blood,
have been reported to phagocytose liposome formulations that are recognized by monocytes
(Karathanasis et al., 2009). A subpopulation of monocytes express CD15 in addition to
CD14, thus these antibodies were used together in the present study to be able to distinguish
between CD15+/CD14− neutrophils and CD14+ monocytes (Fig. 3.2A).
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Figure 3.2: Cellular association of liposome formulations containing POPC (formulation 3 and 4
in Table 3.1) with or without addition of negative (POPG, formulation 1 and 2) or
positive (DOTAP, formulation 5 and 8) lipids. (A) Antibodies used as markers for five
different cell populations in whole blood samples; CD14 (monocytic marker), CD15
(neutrophilic marker), CD3 (T-lymphocytic marker), CD19 (B-lymphocytic marker),
and CD56 (NK cell marker). (B) FACS analysis of the uptake of the six different
liposome formulations (0.5 mM) containing rhodamine B after 1 h incubation at 37◦C.
The data are expressed as percentages of cells positive for rhodamine B shown as mean
± SD (*** P<0.001, **** P<0.0001). (C) Representative graphs showing gating of
positive cells in the 5 cell populations.
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The cationic formulation containing 10 % DOTAP were strongly associated with mono-
cytes (Fig. 3.2B, DOTAP) after 1 h incubation, where 70 % of the monocytes showed
liposome association. The addition of 5 mol% PEG reduced the association of cationic li-
posomes with monocytes significantly (p<0.001), as expected based on the known shielding
effect of PEG-coated liposomes (Romberg et al., 2008) (Fig. 3.2B, DOTAP:PEG, Fig.3.2C,
most upper right two diagrams).
3.4.2 Dynamics of liposome monocyte interaction
For efficient targeting to monocytes in vivo, it is crucial to obtain a fast association with the
monocytes, in particular for non-pegylated liposomes which is rapidly recognized by the MPS
and removed from the circulation (Gabizon et al., 1991). The association rate of liposomes
with leucocytes was investigated over time, where we incubated POPC and 10 % DOTAP
liposomes with freshly drawn human blood under rotation. Samples were collected after 5,
15, and 60 min, and the association of liposomes with leukocytes were analysed by FACS.
POPC liposomes did not interact with any of the investigated leukocytes for the incubation
period of 60 min (Fig. 3.3A), but when incubated with 10 % DOTAP liposomes, there was a
time dependent increase in association of liposomes with CD14+ cells, with 35 % of the cells
associated with liposomes after only 5 min incubation, 40 % after only 15 min incubation,
and approximately 70 % after 60 min incubation (Fig. 3.3B). The DOTAP liposomes only
weakly associated with the other leukocytes investigated, with fewer than 5 % of the cells
associated with the liposomes, except for B-cells, which approached 10 % rhodamine positive
cells after 60 min incubation.
We next analyzed dose-dependent association of the liposomes with leukocytes, at con-
centrations similar to the initial concentration seen after e.g. administration of the liposomal
formulation Doxil, which is given at 20-50 mg/m2, dependent of the type of disease, re-
sulting in a peak plasma concentration (Cmax) of 9-30 mg/L (dox, 2005; Bogner et al.,
1994). The Doxil formulation has a lipid concentration of 22 mM and a doxorubicin con-
centration of 2 mg/mL (dox, 2005), resulting in a lipid-concentration of approximately 0.1
- 0.3 mM. At concentrations ranging from 0.1 to 1.0 mM, similar distribution to leukocytes
were observed, with major association to monocytes at all three doses (p<0.0001). B-cells
increased liposome association to a maximum of 10 % of the cells at the highest liposome
concentration. Again, no association of the POPC liposomes were observed with leukocytes
at the concentrations tested, demonstrating that monocytes specifically associated with the
positively charged liposomes (Fig. 3.3C and D).
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Figure 3.3: Effect of incubation time, concentration, and charge on cellular association of lipo-
somes. Cellular association of liposome formulation 3 (A, POPC) and 8 (B, DOTAP)
after 0, 5, 15, and 60 min incubation (0.5 mM). Cellular association of liposome for-
mulation 3 (C, POPC) and 8 (D, DOTAP) at concentrations of 0, 0.1, 0.5, and 1 mM
after 60 min incubation. (E) Association of liposome formulations containing 0 - 50
% DOTAP. Data are expressed as percentages of cells positive for rhodamine B shown
as mean ± SD (*** P<0.001, **** P<0.0001, ns = not significant).
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3.4.3 Liposomal surface charge density requirements for monocyte specific targeting
Monocytes showed a strong affinity for association with the positively charged liposomes
containing 10 % DOTAP. We wanted to elucidate how variations in liposomal surface charge
affected the association of monocyte with liposomes. Therefore, liposomes with increased
charge from 5 to 50 % DOTAP were prepared and incubated with freshly drawn human
blood for 1 h at 37◦C. Liposomes consisting of POPC and 5 % DOTAP did not associate
specifically with any cell type (Fig. 3.3E). Liposomes with 7.5 and 10 % DOTAP showed
a strong preferential association with CD14+ monocytes, compared to both B-cells (CD19)
(p<0.05 and p<0.0001, respectively) and, neutrophils (CD15), T-lymphocytes (CD3), and
natural killer cells (CD56) (p<0.0001). 12.5 and 15 % DOTAP in the liposomes resulted in
enhanced monocyte-association with approximately 90 % of the cells associated with lipo-
somes, however, the proportion of liposome associated B-cells increased to approximately 27
and 59 %, respectively, and approximately 10 - 20 % of the other leukocytes were associated
with the liposomes. Liposomes containing 20 % DOTAP showed 95 % association with both
monocytes and B-cells, with approximately 35 - 45 % of the other leukocytes associated with
liposomes. At 50 % DOTAP all leukocytes associated strongly with the liposomes. Thus,
liposomes containing 7.5 - 10 mol% DOTAP, with a zeta-potential between 31 - 38 mV,
showed the strongest monocyte specific association.
3.4.4 Specific targeting of monocytes required freshly drawn peripheral blood
A number of in vitro studies analyzing liposome-cell association have been published on
purified primary immune cells, which have normally been processed for several hours prior to
experimentation (Finkelstein et al., 1981; Lee et al., 1993). Additionally, the sera added in
these studies were not fresh, but were from a frozen stock. Studies have also been conducted
on whole blood (Karathanasis et al., 2009; Constantinescu et al., 2003; Kuhn et al., 1983),
however, these studies analyzed all leukocytes as one population, and did not evaluate the
specific association with monocytes. For our studies, we wanted to use freshly drawn human
blood in order to mimic the in vivo situation as closely as possible, in particular because
components of the complement system, such as complement component 3 (C3) fragments
(Wassef & Alving, 1993), known to influence liposome pharmacokinetics, have very short
half-lives both in vivo and in vitro. We therefore wanted to investigate whether freshly
drawn blood showed different liposome binding kinetics compared to blood that was allowed
to age.
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To investigate the importance of these aspects, the blood was left for 2 h and 4 h at 37◦C
with rotation before the liposome association study was performed (Fig. 3.4). The blood
cells did not associate with POPC liposomes at any of the time points investigated (Fig.
3.4A). At 0 h the uptake of 10 % DOTAP was as previously shown significantly higher for
CD14+ cells as compared with the four other leukocyte populations (Fig. 3.4B). After 2 h
pre-incubation of the blood, the percentage of CD14+ monocytes that was associated with
10 % DOTAP liposomes, decreases significantly compared with CD14+ cells at 0 h (p<0.05).
In addition, significantly more CD19+ B-lymphocytes were associated with liposomes after 2
h pre-incubation compared with CD19 cells at 0 h (p<0.001). After 2 h and 4 h there was
no significant difference between association with CD14+ and CD19+ cells, but a significant
increase in association with CD19+ B-cells, and a significant decrease in association with
CD14+ monocytes. These results demonstrate that factors present in fresh blood are involved
in association and possibly targeting to or phagocytosis of nanoparticles by monocytes and B-
cells, and that the mechanisms of cellular uptake of particles in vivo must be carefully studied
in vitro, using freshly isolated blood in order to mimic the in vivo effects. Furthermore, these
data suggests, that the mechanisms of cellular uptake of positively charged liposomes are
different between monocytes and B-cells.
Figure 3.4: In vitro effect of the freshness of peripheral blood. Association of liposome formulation
3 (A, POPC) and 8 (B, DOTAP) after 0, 2, and 4 h incubation of the blood at 37◦C
with rotation (0.5 mM liposomes). Data are expressed as percentages of cells positive
for rhodamine B shown as mean ± SD (* P<0.05, *** P<0.001, **** P<0.0001).
3.4.5 Cytotoxicity of cationic liposomes
Cationic liposomes formulated with different types of nucleic acids have been reported to be
toxic to cells (Lv et al., 2006). We wanted to analyse whether the present empty cationic
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liposomes showed cytotoxic effects on monocytes, however, undifferentiated monocytes are
difficult to maintain in culture due to spontaneous apoptosis (Fahy et al., 1999). Thus,
liposome cytotoxicity was analysed on the human monocytic cell line THP-1 using different
cationic liposome formulations (composition 3 and 6 - 12 in Table 3.1). The cells were
incubated with the liposomes for 1 h before washing, and the liposome association with
THP-1 cells was immediately analyzed by FACS (Fig. 3.5A).
Figure 3.5: Potential cytotoxic effect of liposomes. Apoptosis was measured on the human mono-
cytic cell line THP-1 after treatment with liposomes containing 0 - 50 % DOTAP
(composition 3 and 6 -12 in Table 3.1). Four different concentrations of liposome
were used: 10, 100, 500, and 1000 µM. (A) FACS analysis of association of liposomes
with THP-1 cells after 1 h incubation at 37◦C. (B) Liposomes were incubated with cells
for 1 h before they were washed with media. After 24 h Annexin V binding to the cells
was measured by FACS. Staurosporine was used as positive control for apoptosis. (C)
Representative graphs showing gating of annexin V positive cells. Data are expressed
as percentages of cells positive for (A) rhodamine B or (B) annexin V shown as mean
± SD (*** P<0.001, **** P<0.0001, ns = not significant).
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Apoptosis was measured by analyzing annexin V expression on the cells after 24 h incuba-
tion in fresh media(Fig. 3.5B and C). Annexin V binds with high affinity to phosphatidylserine
that translocates from the inner to the outer layer of the plasma membrane during the early
events in apoptosis (Vermes & Haanen, 1994). Annexin V bound to 70 % of cells treated for
1 h with the known inducer of apoptosis; Staurosporine. There was no significant cytotox-
icity of the cationic liposomes containing up to 20 % DOTAP compared to untreated cells,
whereas the liposome formulation with 50 % DOTAP showed significant annexing V binding
at 500 and 1000 µM, indicating that only this specific formulation was cytotoxic after 24 h
incubation.
A proliferation assay was also conducted on the cells after 24 h to analyze the viability of
liposome treated cells. Liposome induced cytotoxicity was measured by incubating THP-1
cells with XTT for 4 h. As observed with annexin V binding, liposomes containing 50 mol%
DOTAP were toxic to cells at high concentrations (500 and 1000 µM) (Fig. 3.6A), and this
cytotoxicity was clearly seen on the cells also by phase contrast microscopy (Fig. 3.6B).
Figure 3.6: Potential cytotoxic effect of liposomes. Cell viability was measured on the human
monocytic cell line THP-1 after treatment with liposomes containing 0 - 50 % DOTAP
(composition 3 and 6 - 12 in 3.1). Four different concentrations of liposome were used:
10, 100, 500, and 1000 µM. (A) Liposomes were incubated with cells for 1 h before
washing with cell media. After 24 h the liposome induced cytotoxicity was measured
by incubation with XTT for 4 h. (B) Phase contrast microscopy pictures showing cells
after XTT incubation. Data are expressed as absorbance shown as mean ± SD (***
P<0.001, **** P<0.0001).
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Monocytes are involved in development and progression of inflammatory diseases as they
in response to cytokines migrate into tissues where they differentiate into macrophages or
DCs. An imbalance in cytokine release can lead to chronic inflammatory conditions, such as
rheumatoid arthritis, where the excessive amount of monocyte derived macrophages and DCs
in the inflamed tissue contribute to a dysfunctional state by overexpressing proinflammatory
cytokines (Kinne et al., 2007; Schmutz et al., 2010; Woollard & Geissmann, 2010).
In the present study, a novel liposomal drug delivery system was developed for specific
targeting of CD14+ monocytes in human peripheral blood, making it possible to deliver
drugs specific to this population with minimal association with other cell types in the blood.
Neutral, negatively, and positively charged liposome formulations were tested for their ability
to associate with the different cell populations in freshly drawn human blood and it was found
that only positively charged formulations were significantly associated with monocytes.
Our studies revealed that liposome formulations with a positive charge of 7.5 to 10 % were
optimal for targeting to monocytes, while minimal association with other cell populations was
observed. When 12.5 % positively charged lipids were added to the formulation, significantly
more B-lymphocytes were associated with the liposomes than observed with a positive charge
of 10 %. The formulations with 7.5 - 10 % positive charge were only significantly associated
with monocytes and not neutrophils, which also have phagocytosing abilities. Karathanasis
et al. (2009) have previously reported neutrophils to phagocytise liposomes that were rec-
ognized by monocytes in vitro. They used liposomes coated with a synthetic peptide that
resulted in association with both neutrophils and monocytes, which was a result of the spe-
cific amino acid sequence. The peptide contained one positive charge, resulting in liposomes
with a maximal positive charge of 0.12 %, but they found that the charge of the peptide
alone did not determine binding selectivity.
Studies of the interaction between liposomes and blood cells have previously been reported;
however, some of these studies evaluated the leukocytes as one population, and did not
investigate the specific association with monocytes (Finkelstein et al., 1981; Constantinescu
et al., 2003). Furthermore, several of them were conducted on purified PBMCs, where
processing of the cells prior to the study may change their ability for liposomal association
(Finkelstein et al., 1981; Scieszka et al., 1991; Lee et al., 1993; Schenk et al., 2011). In
our study, we found that it was extremely important that the blood was used immediately
after being drawn from the donor, since the ability of the cells to phagocytose the cationic
liposomes changed over time. Already after 2 h preincubation of fresh blood at 37◦C, the
monocytes were significantly impaired in liposome phagocytosis, indicating that phagocytosis
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of liposomes by monocytes depends on factors in fresh blood that are degraded rapidly.
However, this observation may partly be a result of increased number of apoptotic neutrophils,
which have a short half life in the blood (6-12 h) due to commitment into an apoptotic
pathway (Moulding et al., 1999). Thus, after the blood was drawn, the number of apoptotic
cells increased as a function of time. Mikolajczyk et al. (2009) demonstrated that monocytes
phagocytosed apoptotic neutrophils and that they could interfere with this interaction by
addition of PS-containing liposomes, thereby reducing phagocytosis of neutrophils. The
decreased association of liposomes with monocytes observed in our study may be a result of
interference by the increased presence of apoptotic neutrophils in the aged blood, reducing
phagocytosis of liposomes. In contrast to the monocytes, liposome association with B-
lymphocytes was increased as a result of blood ageing.
We aimed at executing the blood assays in vitro in such way that the conditions would
mimic in vivo conditions to the greatest possible extent. However, to be able to conduct these
studies the blood had to be anti-coagulated, which was done with EDTA that chalets calcium
and magnesium ions. Salvador-Morales et al. (2009) demonstrated that lipid-polymer hybrid
nanoparticles mainly activated the alternative pathway of complement. In this study, we
inactivated the classical complement pathway that requires both calcium and magnesium ions,
but unfortunately also the alternative pathway that only requires magnesium ions (Snyderman
& Pike, 1975). However, activation of the alternative pathway due to binding of C3 fragments
has been reported to be a result of high concentrations of cholesterol in the liposomes (Huong
et al., 1998; Ishida et al., 2000). The liposomes used in this delivery system do not contain
cholesterol, which should diminish the complement activation. However, in vivo studies have
to be conducted to ensure that the effect of an active complement system does not change
the monocyte specific association of the liposomes.
Five phagocytosing cell types are present in human blood; B-lymphocytes, neutrophils, and
monocytes as well as small populations of macrophages and DCs. B-lymphocytes have not
previously been reported to be involved in clearance of liposomes unless liposomes are targeted
specifically to these cells (Ishida et al., 2001b). In our studies liposomes were only associated
with monocytes, probably due to variation in the type of liposomal recognition between the
two cell types. Scieszka et al. (1991) have reported that uptake by neutrophils was induced
by binding of C3, whereas monocytes have been reported to recognize apoptotic cells through
an CD14 dependent mechanism through binding to various lipids (Shibuya-Fujiwara et al.,
2001; Mikolajczyk et al., 2009). The latter is consistent with the findings, that CD14+
monocytes have high phagocytotic activity, whereas CD14dim monocytes have low activity
(Cros et al., 2010). Thus, the uptake by monocytes may be a result of recognition of lipids
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in the liposome and independent of opsonins. Furthermore, CD36 have been reported to
be involved in clearance of neutrophils by monocytes through recognition of anionic lipids
(Shibuya-Fujiwara et al., 2001; Mikolajczyk et al., 2009). It is difficult to generalize, since
variation in the lipid content of liposomal formulations have great impact on the recognition
and uptake by blood cells; however, the difference in surface receptors on the various blood
cells result in different recognition of formulations, depending on their specific physiochemical
properties (Drummond et al., 1999; Epstein-Barash et al., 2010). If the liposomal uptake
by neutrophils depended on an active complement system, their uptake may have been
inhibited in our studies due to the experimental conditions that required anti-coagulated
blood. Although Karathanasis et al. (2009) used anti-coagulated blood, they reported uptake
of liposomes in both neutrophils and monocytes.
There has been focus on negatively charged liposomal formulations for targeting the MPS
due to potential risk of cytotoxicity of cationic liposomes (Kelly et al., 2011). Jain et al.
(2003) used negatively charged liposomes with a size of approximately 1 µm, which they
found preferentially to being taken up by neutrophils and monocytes. The uptake by liver
macrophages was significantly decreased, probably due to the size of the liposomes, inhibiting
them from extravasate into the liver. Afergan et al. (2008) reported that negatively charged
liposomes containing cholesterol, with a size of 169.32 ± 36.32 nm, associated with mono-
cytes. In our studies, we did not observe association of negatively charged liposomes with
monocytes. This may partly be due to the fact that our liposomes were small (120 ± 10 nm)
compared to those used by Jain et al. (2003), since the size of liposomes has been reported to
be an important factor for MPS recognition (Juliano & Stamp, 1975). Furthermore, our for-
mulation did not contain cholesterol, which previously has been reported to facilitate uptake
by cells of the MPS through activation of the alternative pathway of complement (Huong
et al., 1998; Ishida et al., 2000). The in vivo study of encapsulated DxM-P performed by
Chono et al. (2005) demonstrated that the enhanced efficacy was a result of the negatively
charged liposomes were recognized by macrophages in the tissues and not monocytes in the
blood, which was consistent with the in vitro studies reported by Lee et al. (1993).
Since cationic liposomes previously have been reported to be cytotoxic to phagocytosing
cells (Filion & Phillips, 1997; Dass et al., 2002), they have not been attractive candidates
for delivery of drugs to the MPS (Kelly et al., 2011). However, many of the investigated
cationic formulations contained high ratio of cationic lipids. It has been reported that the
cytotoxic effect of cationic lipids could be circumvented by addition of co-lipids or co-polymers
in the liposome formulation (Lv et al., 2006). The monocyte targeting formulation in our
study, containing 10 % positively charged lipid, was demonstrated not to be cytotoxic to the
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human acute monocytic leukemia cell line THP-1. However, addition of 50 % the positive
lipid DOTAP, which also was used in the study by Filion & Phillips (1997), induced apoptosis
in this cell line, consistent with previous findings (Filion & Phillips, 1997; Dass et al., 2002).
All lipids used in our novel drug delivery system have marked approval, minimizing the risk
of lipid-associated toxicity.
Cationic liposomes have been used in gene delivery, due to their efficient delivery of siRNA
in vitro (Dass & Choong, 2006; Zuhorn et al., 2007). In addition, they have more recently
been suggested as vaccine adjuvants, as they protect the antigen from degradation and fa-
cilitate uptake by cells of the MPS. In addition, the encapsulated antigen can be formulated
in combination with various immune potentiators (Christensen et al., 2011). The immunos-
timulating compound MTP-PE used in the liposomal formulation Mepact R© would therefore
potentially benefit from encapsulation in our novel cationic formulation. Bal et al. (2011)
recently demonstrated that DOTAP-based liposomes enhanced the immunostimulatory ef-
fect of both TLR-2 and TLR-9 ligands in vitro after liposomal stimulation of DC. They used
cationic liposomes consisting of soybean PC, DOTAP, and DOPE (9:1:1 mol%) resulting
in liposomes with 9 % positively charged DOTAP, but they did not investigate the specific
interaction of the liposomes with cell populations in the blood. Furthermore, Banerjee et al.
(2008) reported that encapsulation of amphotericin B in cationic liposomes, containing 11
% of the positively charged lipid stearylamine, was superior to both free amphotericin B and
AmBisome R© for treatment of visceral leishmaniasis in hamsters, demonstrating enhanced
drug efficacy in vivo by changing the physiochemical properties of the formulation. This
effect may be a result of SA in the cationic liposomes that has leishmanicidal activity, but
enhanced association of liposomes with monocytes due to the positive charge may also play
a role. However, they did not investigate the interaction of the formulation with different cell
types. Thus, as far as we know, the specific association of cationic liposomes with monocytes
has not previously been described.
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4 General discussions
Liposomal drug delivery systems are promising candidates for specific delivery to diseased
tissue, since they enhance drug bioavailability while reducing the amount of drug needed
for therapeutic efficacy as well as side effects due to damage of healthy tissues. Improving
treatments that cause severe side effects is of great importance for achieving enhanced
therapeutic efficacy as well as increased life quality of patients.
In this thesis, development of two different novel drug delivery systems is described. One
system was rationally designed to avoid the MPS and accumulated in cancerous tissues, and
the other system was found to target a specific cell population in the blood, the monocytes.
The most important findings reported in this thesis are:
1) Cancer cell lines in vitro and cancerous tissues in vivo expressed active MMP-2, whereas
only latent forms of the enzymes were present in healthy tissues, validating MMP-2 as
a trigger of drug release in tumor tissue.
2) The MMP-sensitive trigger mechanism could be activated by enzymatic activity result-
ing in enhanced liposomal association with cells in vitro.
3) The HT1080 in vivo model and patient derived xenograft in vivo models of colon cancer
demonstrated high gelatinase activity and can be used for future in vivo evaluation of
the MMP sensitive drug delivery system.
4) The pegylated drug delivery system was able to avoid recognition by the phagocytosing
cells in the blood.
5) A cationic formulation with 7.5 - 10 % positive charge specifically targeted monocytes
in freshly drawn human blood.
6) Freshly drawn blood must be used for in vitro studies of liposome uptake in blood cells.
7) Formulations with up to 20 mol% DOTAP were not toxic to THP-1 cells in vitro.
4.1 The MMP sensitive drug delivery system
Cancer is a group of diseases characterized by uncontrolled cell proliferation as a result of
genetic alterations (Hanahan & Weinberg, 2011). These diseases, which vary phenotypically
due to their different tissue of origin, are treated by removing the diseased cells, destroying
them by inducing DNA damage, or inhibiting their proliferation by interfering with specific
molecules involved in tumor growth and progression. When a primary tumor has metasta-
sized the treatment becomes more challenging as it cannot be treated by surgery or radiation
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therapy, since these strategies require the location of the cancer to be known. Thus, treat-
ment rely on systemic distribution of cytotoxic or cytostatic agents (Hubbard & Alberts,
2010). Most drugs used in the clinic with success are cytotoxic agents that not only affect
the diseased cells, but also destroy healthy cells, especially cells that divide fast under normal
circumstances (Darzynkiewicz et al., 2009). Therefore, specific delivery of drugs to cancer
cells could significantly reduce side effects associated with these drugs, while at the same
time increase treatment due to enhanced delivery to tumor tissue.
In the research field of drug delivery, liposomes have been in focus for decades, due to
their great potential as drug carriers in cancer chemotherapy (Gregoriadis et al., 1974). One
of the major drawbacks of early liposomal drug delivery systems was their rapid recognition
and removal from the circulation by cells of the MPS, a problem that later was circumvented
by coating liposomes with PEG, resulting in significantly prolonged circulation-time due to
decreased uptake by the MPS (Allen & Chonn, 1987). After this discovery, these microscopic
delivery vesicles were found to have great potential for delivery of drugs in cancer treatment,
due to their passive accumulation in cancerous tissues with fenestrated blood vessels. The
formulations used in this study are coated with a novel lipid-peptide-PEG conjulate (RJ111),
which should enhance the circulation time of the liposomes and result in accumulation of
liposomes as previously described (Allen & Hansen, 1991; Blume & Cevc, 1990). Tumor
vasculature have been reported to have a pore size of 100-780 nm, hence our formulation
with a size of 120 ± 10 nm will be able to extravasate into the tumor interstitium and deliver
the loaded drugs (Drummond et al., 1999).
Although liposomes in theory have great potential in cancer treatment, the development
of drug delivery systems that significantly increased patient survival has been challenging.
The only drug class that has been formulated with success is the anthracyclines, which is
assumed to be a result of the special active loading of drug into pre-formulated liposomes
(Barenholz, 2001). Passively loaded liposomes with e.g. cisplatin (SPI-077) do not have an
increased therapeutic effect in vivo, probably due to lack of a mechanism for drug release
(Seetharamu et al., 2010). The presence of an active trigger mechanism for drug release is
extremely important for enhanced efficacy of liposomal formulations. This was demonstrated
by Ishida et al. (2001b), who observed a significantly increased therapeutic efficacy of the
DOX containing anti-CD19-targeted pH-sensitive formulation compared to that of a stable
long-circulating formulation of anti-CD19-targeted liposomes. Hence, to achieve sufficient
drug bioavailability in tumor tissue targeting the tissue alone may not be enough.
The development of drug delivery systems with a site specific trigger mechanism are there-
fore of great interest and several approaches have been investigated utilizing acid, heat, light,
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and enzymatic activity for triggered release. Acid triggered release requires that the drugs
escape the endosomes before they are delivered to the lysosomes for degradation, which
depends on the chemical stability of the drug and fusogenic properties of the liposomes. An-
thracyclines, often used as a model drug in development of delivery systems, are very stable
in acid and may therefore have a long half-life in endosomes, however, not all types of drugs
survive in the harsh milieu in these structures (Andresen et al., 2005). To be able to use
heat and light as a trigger of release, the site of the tumor must be known, hence limiting
the use to primary, non-metastatic tumors at accessible sites. Enzymatic release has gained
increased attention due to the possibility of using enzymes upregulated in cancerous tissues,
such as PLA2 (Jespersen et al., 2012) or the gelatinases (Sarkar et al., 2005; Hatakeyama
et al., 2007b; Terada et al., 2006). MMP-9 has been reported to be able to release the
content of liposomes containing a specific triple-helical lipopeptide substrate (Sarkar et al.,
2005, 2008; Elegbede et al., 2008). However, they have not investigated the efficacy of the
release mechanism, which results in extracellular release of drugs, on cancer cells in vitro or
in vivo. Extracellular release of drugs require that the drug can cross the cell membrane if it
acts intracellularly, reducing the types of drugs that can be delivered by this system.
To enhance delivery of chemotherapeutics and be able to deliver a wide range of drugs,
several strategies of intracellular delivery have been investigated. These involved removal
of PEG, since it has become obvious that the protection from cell association by PEG also
protects the liposomes from association with cancer cells after accumulation (Mishra et al.,
2004; Romberg et al., 2008). Hatakeyama et al. (2007b) and Terada et al. (2006) both
developed systems, where the PEG coat was shredded due to cleavage of a MMP-2 substrate
sequence in a lipopeptide-PEG conjugate. After MMP-2 cleavage the system developed by
Hatakeyama et al. (2007b) enhanced transfection of HT1080 cells in vitro and in vivo.
Jung et al. (2009) used another approach, where cationic liposomes were complexed with
PEG that passively dissociated from the liposomes. However, they found that the PEG did
not reduce the toxicity in vitro and that the formulation was not superior to the neutral
pegylatede formulation Doxil in vivo. The idea of utilizing a combination of removal of
PEG and the enhanced cell association of cationic liposomes had great potential, however,
the design of the system was not optimal, probably due to lack of PEG dissociation after
accumulation in the tumor tissue. We have utilized the same combination, however, in our
system PEG is removed by MMP-2 activity in cancerous tissues. Furthermore, our system is
neutral prior to cleavage, potentially resulting in accumulation comparable to that of non-
charged pegylated formulations, such as Doxil. In our studies, the enzymatic removal of the
negatively charged PEG resulted in a change of the liposomal charge from neutral to positive,
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which facilitated enhanced association between liposomes and cells in vitro. The enhanced
association will probably result in internalization of liposomes in vivo, and their ability to
escape the endosomes must be evaluated in vivo and may therefore require subsequent
optimization of the liposome composition.
Use of DOX as a model drug in evaluation of triggered release has been suggested to
lead to misleading results due to drug leak out of the liposomes. Improved efficacy does
not necessarily provide proof of the release principle in in vivo studies, since DOX passively
diffuse out of intact liposomes, why more hydrophilic drugs should be used in development
of delivery strategies (Andresen et al., 2005). We used oxaliplatin in our studies as this drug,
which is used in the clinic for treatment of colorectal cancer, cannot diffuse passively out of
the liposomes after accumulation at the site of the tumor, hence the efficacy observed in in
vivo studies will be a result of enhanced cellular uptake of liposomes. Oxaliplatin has low
bioavailability due to partitioning into erythrocytes and will therefore benefit greatly from
liposomal encapsulation (Pendyala & Creaven, 1993; Suzuki et al., 2008; Lila et al., 2009).
The liposomal formulation reported here has great prospects due to its novel site-specific
active drug release mechanism, resulting in intracellular delivery of the loaded drugs. How-
ever, the drug delivery system should be evaluated in the HT1080 tumor model for demon-
stration of the enzymatic activation mechanism in presence of MMP-2 in vivo, where the
sustained secretion and activation of enzymes in the extracellular space potentially will ac-
tivate the liposomes. Furthermore, in vivo studies with the non-cleavable D-analogue are
required to confirm that the enhanced efficacy is a result of liposome activation, and not only
due to accumulation of liposomes at the tumor site due to the PEG coating. The results
so far indicate that this delivery system has great potential for improving efficacy of drugs
currently used in cancer treatment.
4.2 The monocyte specific delivery system
In the early days of liposome research, the main focus was on selective delivery of chemother-
apeutics to tumors in the treatment of cancer. The uptake by the MPS was considered an
huge disadvantage in the process of acquiring sufficient drug accumulation at the site of the
tumor in order to achieve enhanced therapeutic efficacy. However, the possibility of targeting
cells of the MPS was eventually considered an opportunity for modulating the action of in-
flammatory cells (Kelly et al., 2011). The cells of the MPS that have been the major target for
liposomal delivery are monocytes in the blood and tissue macrophages due to the important
role these cells play in inflammatory conditions. They are the main producers of inflam-
matory cytokines, and sustained release of these factors can result in chronic inflammation
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(Serhan & Savill, 2005), thus these cells have been found to be involved in the development
and progression of inflammatory diseases, such as atherosclerosis and rheumatoid arthritis
(Woollard & Geissmann, 2010; Schmutz et al., 2010).
Anti-inflammatory GC are widely used in the treatment of inflammatory conditions; how-
ever, these drugs have side effects after prolonged treatment due to their natural functions
in the body, where they are involved in regulation of the metabolism of most organs and tis-
sues, resulting in complication similar to those observed in patients with Cushing’s syndrome
(Peppa et al., 2011). The possibility of encapsulating these drugs in liposomes, reducing
their systemic exposure to tissues, and target them to specific cells would improve side effect
significantly as lower or less frequent doses could be administrated. Encapsulation of im-
munosuppressive drugs has been demonstrated to enhance drug bioavailability while reducing
side effects in animal models (Anderson et al., 2010; Chono et al., 2005). Many studies have
investigated the uptake by macrophages, which secrete proinflammatory cytokines in the tis-
sues; however this requires that the liposomes come in contact with the cells in the tissues
(Lee et al., 1993; Chono et al., 2005; Epstein-Barash et al., 2010). One major drawback
of this approach is that formulations recognized by macrophages in diseased tissues also are
phagocytosed by macrophages in the spleen and liver, the major organs of liposome clear-
ance (Ishida et al., 2002), thus, we aimed at specific targeting to monocytes. This strategy
enables enhanced delivery to inflammatory cells with less liposomes cleared by macrophages,
reported to recognize negatively charged liposomes (Lee et al., 1993; Chono et al., 2005).
In our in vitro studies the complement system was inactivated due to addition of EDTA,
which binds magnesium and calcium ions and thereby inactivates the enzymes needed for
initiation of the coagulation cascade. This unfortunately also inhibited the complement cas-
cade. The complement factors C3 and C5 have been described to be involved in phagocytosis
of liposomes by neutrophils (Scieszka et al., 1991); however, the liposomes used contained
high levels of cholesterol (40 mol%), previously reported to activate of the alternative path-
way due to binding of C3 fragments (Huong et al., 1998; Ishida et al., 2000). Karathanasis
et al. (2009) reported liposomal uptake in both neutrophils and monocytes even though they
have used anti-coagulated blood, hence, cellular association of liposome formulations with
blood cells as well as recognition by macrophages in vivo is difficult to predict.
We have optimized this formulation in what we believe are the conditions that resemble
the in vivo conditions to the best possible extend. The formulation should be evaluated in
vivo, but the optimal way to do this would be by formulating a biological active drug in the
liposomes and test the function instead of only testing biodistribution, from which it may be
difficult to evaluate the specific targeting of monocytes due to experiential procedures and
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localization of monocytes after liposome uptake. This could e.g. be done by formulating
the liposomes with the immunosuppressive DxM, however, the biological efficacy of the
formulation should previously be validated in vitro.
The use of this novel formulation as an immunostimulating formulation is also possible by
incorporating molecules that stimulate the immunesystem, such as MPD, which is commercial
available in a form that can easily be formulated in liposomes as it contains a lipophilic part
(L18-MDP). Such a formulation already exists, however this does not target monocytes
specifically but all MPS cells. Mepact R© is an immunostimulation formulation approved for
use in the clinic, containing MTP that stimulates monocytes and macrophages to enhanced
secretion of pro-inflammatory cytokines. Formulation of MTP in our liposome formulation
could potentially improve the proinflammatory responds at lower drug doses.
In addition, this liposome formulation may also be used in anti-fungal treatment. Ambisome R©
is an anti-fungal liposomal formulation approved for clinical use that has proven extremely
useful in treatment of visceral leishmaniasis, which are parasites within the human phago-
cytes. Our formulation could increase targeting to monocytes decreasing administrated doses
of the toxic drug. It should be taken into account that these parasites are found in neu-
trophils, monocytes, and macrophages, of which not all will be targeted by our formulation.
However, Ambisome R© has been suggested to act by associating with cells of the MPS and
subsequent being transferred to the site of infection (Walsh et al., 1998). In addition, Baner-
jee et al. (2008) demonstrated that encapsulation of amphotericin B in cationic liposomes
could be used for treatment of visceral leishmaniasis in hamsters and that this formulation
was superior to Ambisome R©. Thus, this novel formulation can potentially be used for in
various types of treatments due to the complex action of the target cells, the monocytes.
4.3 Conclusions
In conclusion, we have here demonstrated that the MMP sensitive delivery system can be
enzymatically activated, resulting in enhanced cellular association in vitro. Furthermore, the
liposomes were not recognized by monocytes in the blood, thus, they should be able to
avoid the MPS and accumulate in tumor tissue, due to pegylation and their small size. High
MMP-2 activity, which is able to cleave the substrate sequence in vitro, was found in tumor
tissue, suggesting that the liposomes will be activated in cancerous tissues. Furthermore, we
found that monocytes in human whole blood could be specifically targeted with our cationic
liposome formulation, which can have great impact on future treatment of inflammatory
diseases as well as a vaccine adjuvant.
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